##gff-version 3								
##gvf-version 1.10								
##sample-description sample_desc=Clinical;sample_group=2023-12-25_2023-12-31;								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	.	21	21	.	+	.	ID=ID_0;Name=g.C-245T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=15;ao=8;dp=23;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C-245T;aa_name=;hgvs_nt=NC_045512.2:g.245C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.34782608695652173;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	44	44	.	+	.	ID=ID_1;Name=g.C-222T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=18;ao=2;dp=20;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C-222T;aa_name=;hgvs_nt=NC_045512.2:g.222C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	222	222	.	+	.	ID=ID_2;Name=g.C-44T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1841;ao=11;dp=1852;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C-44T;aa_name=;hgvs_nt=NC_045512.2:g.44C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005939524838012959;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	241	241	.	+	.	ID=ID_3;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=3;ao=1849;dp=1852;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9983801295896328;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	405	405	.	+	.	ID=ID_4;Name=K47R;alias=K47R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1082;ao=770;dp=1852;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A140G;aa_name=p.K47R;hgvs_nt=NC_045512.2:g.140A>G;hgvs_aa=YP_009724389.1:p.Lys47Arg;hgvs_alias=YP_009724389.1:Lys47Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41576673866090713;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	507	507	.	+	.	ID=ID_5;Name=G82_M85delinsV;alias=G82_M85delinsV;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1795;ao=14;dp=1850;sample_size=1924;Reference_seq=ATGGTCATGTTATGGT;Variant_seq=A;nt_name=g.245_253delGTCATGTTA;aa_name=p.G82_M85delinsV;hgvs_nt=NC_045512.2:g.245_253del;hgvs_aa=YP_009724389.1:p.Gly82_Met85delinsVal;hgvs_alias=YP_009724389.1:Gly82_Met85delinsVal;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0075675675675675675;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	507	507	.	+	.	ID=ID_6;Name=G82_V86del;alias=G82_V86del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1795;ao=10;dp=1850;sample_size=1924;Reference_seq=ATGGTCATGTTATGGT;Variant_seq=ATGTGGT;nt_name=g.245_259delGTCATGTTATGGTTG;aa_name=p.G82_V86del;hgvs_nt=NC_045512.2:g.245_259del;hgvs_aa=YP_009724389.1:p.Gly82_Val86del;hgvs_alias=YP_009724389.1:Gly82_Val86del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	670	670	.	+	.	ID=ID_7;Name=S135R;alias=S135R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=3;ao=1851;dp=1855;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T405G;aa_name=p.S135R;hgvs_nt=NC_045512.2:g.405T>G;hgvs_aa=YP_009724389.1:p.Ser135Arg;hgvs_alias=YP_009724389.1:Ser135Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.997843665768194;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	685	685	.	+	.	ID=ID_8;Name=K141_F143del;alias=K141_F143del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1828;ao=26;dp=1855;sample_size=1924;Reference_seq=AAAGTCATTT;Variant_seq=A;nt_name=g.421_429delAAGTCATTT;aa_name=p.K141_F143del;hgvs_nt=NC_045512.2:g.421_429del;hgvs_aa=YP_009724389.1:p.Lys141_Phe143del;hgvs_alias=YP_009724389.1:Lys141_Phe143del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014016172506738544;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	772	772	.	+	.	ID=ID_9;Name=V169V;alias=V169V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1831;ao=26;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T507C;aa_name=p.V169V;hgvs_nt=NC_045512.2:g.507T>C;hgvs_aa=YP_009724389.1:p.Val169Val;hgvs_alias=YP_009724389.1:Val169Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014001077005923533;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	774	774	.	+	.	ID=ID_10;Name=T170I;alias=T170I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1738;ao=119;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C509T;aa_name=p.T170I;hgvs_nt=NC_045512.2:g.509C>T;hgvs_aa=YP_009724389.1:p.Thr170Ile;hgvs_alias=YP_009724389.1:Thr170Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06408185245018848;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	853	853	.	+	.	ID=ID_11;Name=Y196Y;alias=Y16Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1845;ao=12;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C588T;aa_name=p.Y196Y;hgvs_nt=NC_045512.2:g.588C>T;hgvs_aa=YP_009724389.1:p.Tyr196Tyr;hgvs_alias=YP_009724389.1:Tyr16Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006462035541195477;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	897	897	.	+	.	ID=ID_12;Name=A211D;alias=A31D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=777;ao=1078;dp=1856;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C632A;aa_name=p.A211D;hgvs_nt=NC_045512.2:g.632C>A;hgvs_aa=YP_009724389.1:p.Ala211Asp;hgvs_alias=YP_009724389.1:Ala31Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5808189655172413;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	934	934	.	+	.	ID=ID_13;Name=D223D;alias=D43D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1845;ao=10;dp=1855;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C669T;aa_name=p.D223D;hgvs_nt=NC_045512.2:g.669C>T;hgvs_aa=YP_009724389.1:p.Asp223Asp;hgvs_alias=YP_009724389.1:Asp43Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005390835579514825;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1060	1060	.	+	.	ID=ID_14;Name=T265T;alias=T85T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1833;ao=24;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C795T;aa_name=p.T265T;hgvs_nt=NC_045512.2:g.795C>T;hgvs_aa=YP_009724389.1:p.Thr265Thr;hgvs_alias=YP_009724389.1:Thr85Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012924071082390954;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1236	1236	.	+	.	ID=ID_15;Name=D324G;alias=D144G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1852;ao=14;dp=1866;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A971G;aa_name=p.D324G;hgvs_nt=NC_045512.2:g.971A>G;hgvs_aa=YP_009724389.1:p.Asp324Gly;hgvs_alias=YP_009724389.1:Asp144Gly;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007502679528403001;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1579	1579	.	+	.	ID=ID_16;Name=V438V;alias=V258V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1837;ao=18;dp=1862;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1314C;aa_name=p.V438V;hgvs_nt=NC_045512.2:g.1314T>C;hgvs_aa=YP_009724389.1:p.Val438Val;hgvs_alias=YP_009724389.1:Val258Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00966702470461869;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1599	1599	.	+	.	ID=ID_17;Name=G445V;alias=G265V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1820;ao=44;dp=1866;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1334T;aa_name=p.G445V;hgvs_nt=NC_045512.2:g.1334G>T;hgvs_aa=YP_009724389.1:p.Gly445Val;hgvs_alias=YP_009724389.1:Gly265Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.023579849946409433;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1762	1762	.	+	.	ID=ID_18;Name=F499L;alias=F319L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1749;ao=114;dp=1863;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C1497A;aa_name=p.F499L;hgvs_nt=NC_045512.2:g.1497C>A;hgvs_aa=YP_009724389.1:p.Phe499Leu;hgvs_alias=YP_009724389.1:Phe319Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.061191626409017714;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1779	1779	.	+	.	ID=ID_19;Name=S505F;alias=S325F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1814;ao=49;dp=1863;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1514T;aa_name=p.S505F;hgvs_nt=NC_045512.2:g.1514C>T;hgvs_aa=YP_009724389.1:p.Ser505Phe;hgvs_alias=YP_009724389.1:Ser325Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026301663982823402;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1820	1820	.	+	.	ID=ID_20;Name=G519S;alias=G339S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1843;ao=15;dp=1862;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G1555A;aa_name=p.G519S;hgvs_nt=NC_045512.2:g.1555G>A;hgvs_aa=YP_009724389.1:p.Gly519Ser;hgvs_alias=YP_009724389.1:Gly339Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008055853920515575;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1889	1889	.	+	.	ID=ID_21;Name=R542C;alias=R362C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1728;ao=135;dp=1863;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1624T;aa_name=p.R542C;hgvs_nt=NC_045512.2:g.1624C>T;hgvs_aa=YP_009724389.1:p.Arg542Cys;hgvs_alias=YP_009724389.1:Arg362Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07246376811594203;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1912	1912	.	+	.	ID=ID_22;Name=S549S;alias=S369S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1850;ao=15;dp=1865;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1647T;aa_name=p.S549S;hgvs_nt=NC_045512.2:g.1647C>T;hgvs_aa=YP_009724389.1:p.Ser549Ser;hgvs_alias=YP_009724389.1:Ser369Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00804289544235925;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	1973	1973	.	+	.	ID=ID_23;Name=L570L;alias=L390L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1855;ao=10;dp=1865;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1708T;aa_name=p.L570L;hgvs_nt=NC_045512.2:g.1708C>T;hgvs_aa=YP_009724389.1:p.Leu570Leu;hgvs_alias=YP_009724389.1:Leu390Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005361930294906166;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2127	2127	.	+	.	ID=ID_24;Name=Y621C;alias=Y441C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1776;ao=88;dp=1864;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1862G;aa_name=p.Y621C;hgvs_nt=NC_045512.2:g.1862A>G;hgvs_aa=YP_009724389.1:p.Tyr621Cys;hgvs_alias=YP_009724389.1:Tyr441Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04721030042918455;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2128	2128	.	+	.	ID=ID_25;Name=Y621Y;alias=Y441Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1816;ao=48;dp=1864;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1863C;aa_name=p.Y621Y;hgvs_nt=NC_045512.2:g.1863T>C;hgvs_aa=YP_009724389.1:p.Tyr621Tyr;hgvs_alias=YP_009724389.1:Tyr441Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02575107296137339;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2334	2334	.	+	.	ID=ID_26;Name=A690V;alias=A510V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1255;ao=614;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2069T;aa_name=p.A690V;hgvs_nt=NC_045512.2:g.2069C>T;hgvs_aa=YP_009724389.1:p.Ala690Val;hgvs_alias=YP_009724389.1:Ala510Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.328517924023542;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2398	2398	.	+	.	ID=ID_27;Name=T711T;alias=T531T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G2133A;aa_name=p.T711T;hgvs_nt=NC_045512.2:g.2133G>A;hgvs_aa=YP_009724389.1:p.Thr711Thr;hgvs_alias=YP_009724389.1:Thr531Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2433	2433	.	+	.	ID=ID_28;Name=S723F;alias=S543F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1826;ao=44;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2168T;aa_name=p.S723F;hgvs_nt=NC_045512.2:g.2168C>T;hgvs_aa=YP_009724389.1:p.Ser723Phe;hgvs_alias=YP_009724389.1:Ser543Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.023529411764705882;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2485	2485	.	+	.	ID=ID_29;Name=I740I;alias=I560I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1854;ao=16;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2220T;aa_name=p.I740I;hgvs_nt=NC_045512.2:g.2220C>T;hgvs_aa=YP_009724389.1:p.Ile740Ile;hgvs_alias=YP_009724389.1:Ile560Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008556149732620321;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2695	2695	.	+	.	ID=ID_30;Name=N810N;alias=N630N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1836;ao=11;dp=1847;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2430T;aa_name=p.N810N;hgvs_nt=NC_045512.2:g.2430C>T;hgvs_aa=YP_009724389.1:p.Asn810Asn;hgvs_alias=YP_009724389.1:Asn630Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005955603681645912;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2782	2782	.	+	.	ID=ID_31;Name=V839V;alias=V21V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1821;ao=28;dp=1849;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G2517T;aa_name=p.V839V;hgvs_nt=NC_045512.2:g.2517G>T;hgvs_aa=YP_009724389.1:p.Val839Val;hgvs_alias=YP_009724389.1:Val21Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.015143320713899405;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2790	2790	.	+	.	ID=ID_32;Name=T842I;alias=T24I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1848;dp=1848;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2525T;aa_name=p.T842I;hgvs_nt=NC_045512.2:g.2525C>T;hgvs_aa=YP_009724389.1:p.Thr842Ile;hgvs_alias=YP_009724389.1:Thr24Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	2902	2902	.	+	.	ID=ID_33;Name=V879V;alias=V61V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1859;ao=10;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2637T;aa_name=p.V879V;hgvs_nt=NC_045512.2:g.2637C>T;hgvs_aa=YP_009724389.1:p.Val879Val;hgvs_alias=YP_009724389.1:Val61Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005350454788657036;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	3037	3037	.	+	.	ID=ID_34;Name=F924F;alias=F106F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1869;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=YP_009724389.1:Phe106Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	3242	3242	.	+	.	ID=ID_35;Name=G993S;alias=G175S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1760;ao=48;dp=1808;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G2977A;aa_name=p.G993S;hgvs_nt=NC_045512.2:g.2977G>A;hgvs_aa=YP_009724389.1:p.Gly993Ser;hgvs_alias=YP_009724389.1:Gly175Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02654867256637168;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	3330	3330	.	+	.	ID=ID_36;Name=T1022I;alias=T204I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1815;ao=15;dp=1831;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3065T;aa_name=p.T1022I;hgvs_nt=NC_045512.2:g.3065C>T;hgvs_aa=YP_009724389.1:p.Thr1022Ile;hgvs_alias=YP_009724389.1:Thr204Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008192244675040962;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	3431	3431	.	+	.	ID=ID_37;Name=V1056L;alias=V238L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=783;ao=1055;dp=1838;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G3166T;aa_name=p.V1056L;hgvs_nt=NC_045512.2:g.3166G>T;hgvs_aa=YP_009724389.1:p.Val1056Leu;hgvs_alias=YP_009724389.1:Val238Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.573993471164309;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	3565	3565	.	+	.	ID=ID_38;Name=G1100G;alias=G282G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=893;ao=967;dp=1860;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T3300C;aa_name=p.G1100G;hgvs_nt=NC_045512.2:g.3300T>C;hgvs_aa=YP_009724389.1:p.Gly1100Gly;hgvs_alias=YP_009724389.1:Gly282Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5198924731182796;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	3784	3784	.	+	.	ID=ID_39;Name=V1173V;alias=V355V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1855;ao=15;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3519T;aa_name=p.V1173V;hgvs_nt=NC_045512.2:g.3519C>T;hgvs_aa=YP_009724389.1:p.Val1173Val;hgvs_alias=YP_009724389.1:Val355Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008021390374331552;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4005	4005	.	+	.	ID=ID_40;Name=K1247R;alias=K429R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A3740G;aa_name=p.K1247R;hgvs_nt=NC_045512.2:g.3740A>G;hgvs_aa=YP_009724389.1:p.Lys1247Arg;hgvs_alias=YP_009724389.1:Lys429Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4044	4044	.	+	.	ID=ID_41;Name=N1260S;alias=N442S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1855;ao=15;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A3779G;aa_name=p.N1260S;hgvs_nt=NC_045512.2:g.3779A>G;hgvs_aa=YP_009724389.1:p.Asn1260Ser;hgvs_alias=YP_009724389.1:Asn442Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008021390374331552;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4184	4184	.	+	.	ID=ID_42;Name=G1307S;alias=G489S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1865;dp=1865;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G3919A;aa_name=p.G1307S;hgvs_nt=NC_045512.2:g.3919G>A;hgvs_aa=YP_009724389.1:p.Gly1307Ser;hgvs_alias=YP_009724389.1:Gly489Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4280	4280	.	+	.	ID=ID_43;Name=V1339I;alias=V521I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1822;ao=41;dp=1863;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G4015A;aa_name=p.V1339I;hgvs_nt=NC_045512.2:g.4015G>A;hgvs_aa=YP_009724389.1:p.Val1339Ile;hgvs_alias=YP_009724389.1:Val521Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02200751476113795;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4300	4300	.	+	.	ID=ID_44;Name=V1345V;alias=V527V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1852;ao=12;dp=1864;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G4035T;aa_name=p.V1345V;hgvs_nt=NC_045512.2:g.4035G>T;hgvs_aa=YP_009724389.1:p.Val1345Val;hgvs_alias=YP_009724389.1:Val527Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006437768240343348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4321	4321	.	+	.	ID=ID_45;Name=F1353fs;alias=F535fs;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=14;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=TT;nt_name=g.C4056TT;aa_name=p.F1353fs;hgvs_nt=NC_045512.2:g.4056C>T;hgvs_aa=YP_009724389.1:p.Phe1353fs;hgvs_alias=YP_009724389.1:Phe535fs;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0075107296137339056;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4321	4321	.	+	.	ID=ID_46;Name=A1352A;alias=A534A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1849;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C4056T;aa_name=p.A1352A;hgvs_nt=NC_045512.2:g.4056C>T;hgvs_aa=YP_009724389.1:p.Ala1352Ala;hgvs_alias=YP_009724389.1:Ala534Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9919527896995708;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4423	4423	.	+	.	ID=ID_47;Name=R1386R;alias=R568R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1844;ao=20;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C4158T;aa_name=p.R1386R;hgvs_nt=NC_045512.2:g.4158C>T;hgvs_aa=YP_009724389.1:p.Arg1386Arg;hgvs_alias=YP_009724389.1:Arg568Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01072961373390558;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4460	4460	.	+	.	ID=ID_48;Name=V1399I;alias=V581I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1841;ao=10;dp=1851;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G4195A;aa_name=p.V1399I;hgvs_nt=NC_045512.2:g.4195G>A;hgvs_aa=YP_009724389.1:p.Val1399Ile;hgvs_alias=YP_009724389.1:Val581Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005402485143165856;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4795	4795	.	+	.	ID=ID_49;Name=S1510S;alias=S692S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1857;ao=12;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C4530T;aa_name=p.S1510S;hgvs_nt=NC_045512.2:g.4530C>T;hgvs_aa=YP_009724389.1:p.Ser1510Ser;hgvs_alias=YP_009724389.1:Ser692Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006420545746388443;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4921	4921	.	+	.	ID=ID_50;Name=T1552T;alias=T734T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1812;ao=55;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C4656T;aa_name=p.T1552T;hgvs_nt=NC_045512.2:g.4656C>T;hgvs_aa=YP_009724389.1:p.Thr1552Thr;hgvs_alias=YP_009724389.1:Thr734Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029443254817987152;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	4930	4930	.	+	.	ID=ID_51;Name=N1555N;alias=N737N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1856;ao=12;dp=1868;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T4665C;aa_name=p.N1555N;hgvs_nt=NC_045512.2:g.4665T>C;hgvs_aa=YP_009724389.1:p.Asn1555Asn;hgvs_alias=YP_009724389.1:Asn737Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006423982869379015;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	5031	5031	.	+	.	ID=ID_52;Name=T1589I;alias=T771I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1859;ao=10;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C4766T;aa_name=p.T1589I;hgvs_nt=NC_045512.2:g.4766C>T;hgvs_aa=YP_009724389.1:p.Thr1589Ile;hgvs_alias=YP_009724389.1:Thr771Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005350454788657036;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	5646	5646	.	+	.	ID=ID_53;Name=T1794I;alias=T976I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1731;ao=31;dp=1762;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C5381T;aa_name=p.T1794I;hgvs_nt=NC_045512.2:g.5381C>T;hgvs_aa=YP_009724389.1:p.Thr1794Ile;hgvs_alias=YP_009724389.1:Thr976Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.017593643586833144;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	5672	5672	.	+	.	ID=ID_54;Name=P1803S;alias=P985S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1737;ao=18;dp=1755;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C5407T;aa_name=p.P1803S;hgvs_nt=NC_045512.2:g.5407C>T;hgvs_aa=YP_009724389.1:p.Pro1803Ser;hgvs_alias=YP_009724389.1:Pro985Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010256410256410256;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	5720	5720	.	+	.	ID=ID_55;Name=G1819S;alias=G1001S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1204;ao=664;dp=1868;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G5455A;aa_name=p.G1819S;hgvs_nt=NC_045512.2:g.5455G>A;hgvs_aa=YP_009724389.1:p.Gly1819Ser;hgvs_alias=YP_009724389.1:Gly1001Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3554603854389722;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	5835	5835	.	+	.	ID=ID_56;Name=S1857L;alias=S1039L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1546;ao=323;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C5570T;aa_name=p.S1857L;hgvs_nt=NC_045512.2:g.5570C>T;hgvs_aa=YP_009724389.1:p.Ser1857Leu;hgvs_alias=YP_009724389.1:Ser1039Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.17281968967362227;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6183	6183	.	+	.	ID=ID_57;Name=K1973R;alias=K1155R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=782;ao=1087;dp=1869;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A5918G;aa_name=p.K1973R;hgvs_nt=NC_045512.2:g.5918A>G;hgvs_aa=YP_009724389.1:p.Lys1973Arg;hgvs_alias=YP_009724389.1:Lys1155Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5815944355270198;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6317	6317	.	+	.	ID=ID_58;Name=P2018S;alias=P1200S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1836;ao=34;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6052T;aa_name=p.P2018S;hgvs_nt=NC_045512.2:g.6052C>T;hgvs_aa=YP_009724389.1:p.Pro2018Ser;hgvs_alias=YP_009724389.1:Pro1200Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01818181818181818;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6541	6541	.	+	.	ID=ID_59;Name=H2092H;alias=H1274H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1734;ao=135;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6276T;aa_name=p.H2092H;hgvs_nt=NC_045512.2:g.6276C>T;hgvs_aa=YP_009724389.1:p.His2092His;hgvs_alias=YP_009724389.1:His1274His;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07223113964686999;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6701	6701	.	+	.	ID=ID_60;Name=L2146F;alias=L1328F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1852;ao=14;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6436T;aa_name=p.L2146F;hgvs_nt=NC_045512.2:g.6436C>T;hgvs_aa=YP_009724389.1:p.Leu2146Phe;hgvs_alias=YP_009724389.1:Leu1328Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007502679528403001;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6896	6896	.	+	.	ID=ID_61;Name=L2211L;alias=L1393L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1788;ao=81;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6631T;aa_name=p.L2211L;hgvs_nt=NC_045512.2:g.6631C>T;hgvs_aa=YP_009724389.1:p.Leu2211Leu;hgvs_alias=YP_009724389.1:Leu1393Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04333868378812199;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6982	6982	.	+	.	ID=ID_62;Name=C2239C;alias=C1421C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1859;ao=10;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6717T;aa_name=p.C2239C;hgvs_nt=NC_045512.2:g.6717C>T;hgvs_aa=YP_009724389.1:p.Cys2239Cys;hgvs_alias=YP_009724389.1:Cys1421Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005350454788657036;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	6990	6990	.	+	.	ID=ID_63;Name=S2242F;alias=S1424F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1853;ao=16;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6725T;aa_name=p.S2242F;hgvs_nt=NC_045512.2:g.6725C>T;hgvs_aa=YP_009724389.1:p.Ser2242Phe;hgvs_alias=YP_009724389.1:Ser1424Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008560727661851257;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7086	7086	.	+	.	ID=ID_64;Name=T2274I;alias=T1456I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1734;ao=135;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C6821T;aa_name=p.T2274I;hgvs_nt=NC_045512.2:g.6821C>T;hgvs_aa=YP_009724389.1:p.Thr2274Ile;hgvs_alias=YP_009724389.1:Thr1456Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07223113964686999;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7393	7393	.	+	.	ID=ID_65;Name=P2376P;alias=P1558P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1860;ao=10;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G7128A;aa_name=p.P2376P;hgvs_nt=NC_045512.2:g.7128G>A;hgvs_aa=YP_009724389.1:p.Pro2376Pro;hgvs_alias=YP_009724389.1:Pro1558Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7564	7564	.	+	.	ID=ID_66;Name=S2433S;alias=S1615S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1797;ao=14;dp=1811;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C7299T;aa_name=p.S2433S;hgvs_nt=NC_045512.2:g.7299C>T;hgvs_aa=YP_009724389.1:p.Ser2433Ser;hgvs_alias=YP_009724389.1:Ser1615Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007730535615681944;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7600	7600	.	+	.	ID=ID_67;Name=C2445C;alias=C1627C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1801;ao=15;dp=1816;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C7335T;aa_name=p.C2445C;hgvs_nt=NC_045512.2:g.7335C>T;hgvs_aa=YP_009724389.1:p.Cys2445Cys;hgvs_alias=YP_009724389.1:Cys1627Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008259911894273128;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7764	7764	.	+	.	ID=ID_68;Name=S2500F;alias=S1682F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1755;ao=50;dp=1805;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C7499T;aa_name=p.S2500F;hgvs_nt=NC_045512.2:g.7499C>T;hgvs_aa=YP_009724389.1:p.Ser2500Phe;hgvs_alias=YP_009724389.1:Ser1682Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.027700831024930747;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7842	7842	.	+	.	ID=ID_69;Name=N2526S;alias=N1708S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=781;ao=1089;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A7577G;aa_name=p.N2526S;hgvs_nt=NC_045512.2:g.7577A>G;hgvs_aa=YP_009724389.1:p.Asn2526Ser;hgvs_alias=YP_009724389.1:Asn1708Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5823529411764706;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	7932	7932	.	+	.	ID=ID_70;Name=S2556L;alias=S1738L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1857;ao=13;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C7667T;aa_name=p.S2556L;hgvs_nt=NC_045512.2:g.7667C>T;hgvs_aa=YP_009724389.1:p.Ser2556Leu;hgvs_alias=YP_009724389.1:Ser1738Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006951871657754011;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8074	8074	.	+	.	ID=ID_71;Name=N2603N;alias=N1785N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1858;ao=12;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C7809T;aa_name=p.N2603N;hgvs_nt=NC_045512.2:g.7809C>T;hgvs_aa=YP_009724389.1:p.Asn2603Asn;hgvs_alias=YP_009724389.1:Asn1785Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006417112299465241;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8122	8122	.	+	.	ID=ID_72;Name=E2619E;alias=E1801E;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1850;ao=20;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A7857G;aa_name=p.E2619E;hgvs_nt=NC_045512.2:g.7857A>G;hgvs_aa=YP_009724389.1:p.Glu2619Glu;hgvs_alias=YP_009724389.1:Glu1801Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0106951871657754;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8220	8220	.	+	.	ID=ID_73;Name=V2652A;alias=V1834A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1829;ao=41;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T7955C;aa_name=p.V2652A;hgvs_nt=NC_045512.2:g.7955T>C;hgvs_aa=YP_009724389.1:p.Val2652Ala;hgvs_alias=YP_009724389.1:Val1834Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021925133689839574;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8293	8293	.	+	.	ID=ID_74;Name=T2676T;alias=T1858T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=779;ao=1091;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C8028T;aa_name=p.T2676T;hgvs_nt=NC_045512.2:g.8028C>T;hgvs_aa=YP_009724389.1:p.Thr2676Thr;hgvs_alias=YP_009724389.1:Thr1858Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5834224598930481;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8320	8320	.	+	.	ID=ID_75;Name=P2685P;alias=P1867P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1859;ao=10;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C8055T;aa_name=p.P2685P;hgvs_nt=NC_045512.2:g.8055C>T;hgvs_aa=YP_009724389.1:p.Pro2685Pro;hgvs_alias=YP_009724389.1:Pro1867Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005350454788657036;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8393	8393	.	+	.	ID=ID_76;Name=A2710T;alias=A1892T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=781;ao=1089;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G8128A;aa_name=p.A2710T;hgvs_nt=NC_045512.2:g.8128G>A;hgvs_aa=YP_009724389.1:p.Ala2710Thr;hgvs_alias=YP_009724389.1:Ala1892Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5823529411764706;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8737	8737	.	+	.	ID=ID_77;Name=D2824D;alias=D61D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1857;ao=13;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T8472C;aa_name=p.D2824D;hgvs_nt=NC_045512.2:g.8472T>C;hgvs_aa=YP_009724389.1:p.Asp2824Asp;hgvs_alias=YP_009724389.1:Asp61Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006951871657754011;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8849	8849	.	+	.	ID=ID_78;Name=V2862L;alias=V99L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1854;ao=16;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G8584T;aa_name=p.V2862L;hgvs_nt=NC_045512.2:g.8584G>T;hgvs_aa=YP_009724389.1:p.Val2862Leu;hgvs_alias=YP_009724389.1:Val99Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008556149732620321;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	8947	8947	.	+	.	ID=ID_79;Name=N2894N;alias=N131N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1853;ao=16;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C8682T;aa_name=p.N2894N;hgvs_nt=NC_045512.2:g.8682C>T;hgvs_aa=YP_009724389.1:p.Asn2894Asn;hgvs_alias=YP_009724389.1:Asn131Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008560727661851257;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9142	9142	.	+	.	ID=ID_80;Name=G2959G;alias=G196G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1813;ao=57;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C8877T;aa_name=p.G2959G;hgvs_nt=NC_045512.2:g.8877C>T;hgvs_aa=YP_009724389.1:p.Gly2959Gly;hgvs_alias=YP_009724389.1:Gly196Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03048128342245989;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9344	9344	.	+	.	ID=ID_81;Name=L3027F;alias=L264F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9079T;aa_name=p.L3027F;hgvs_nt=NC_045512.2:g.9079C>T;hgvs_aa=YP_009724389.1:p.Leu3027Phe;hgvs_alias=YP_009724389.1:Leu264Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9424	9424	.	+	.	ID=ID_82;Name=V3053V;alias=V290V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A9159G;aa_name=p.V3053V;hgvs_nt=NC_045512.2:g.9159A>G;hgvs_aa=YP_009724389.1:p.Val3053Val;hgvs_alias=YP_009724389.1:Val290Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9534	9534	.	+	.	ID=ID_83;Name=T3090I;alias=T327I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9269T;aa_name=p.T3090I;hgvs_nt=NC_045512.2:g.9269C>T;hgvs_aa=YP_009724389.1:p.Thr3090Ile;hgvs_alias=YP_009724389.1:Thr327Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9693	9693	.	+	.	ID=ID_84;Name=A3143V;alias=A380V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1254;ao=612;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9428T;aa_name=p.A3143V;hgvs_nt=NC_045512.2:g.9428C>T;hgvs_aa=YP_009724389.1:p.Ala3143Val;hgvs_alias=YP_009724389.1:Ala380Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3279742765273312;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9774	9774	.	+	.	ID=ID_85;Name=V3170A;alias=V407A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1855;ao=11;dp=1866;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T9509C;aa_name=p.V3170A;hgvs_nt=NC_045512.2:g.9509T>C;hgvs_aa=YP_009724389.1:p.Val3170Ala;hgvs_alias=YP_009724389.1:Val407Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005894962486602358;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	9866	9866	.	+	.	ID=ID_86;Name=L3201F;alias=L438F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1086;ao=779;dp=1865;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9601T;aa_name=p.L3201F;hgvs_nt=NC_045512.2:g.9601C>T;hgvs_aa=YP_009724389.1:p.Leu3201Phe;hgvs_alias=YP_009724389.1:Leu438Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41769436997319037;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10015	10015	.	+	.	ID=ID_87;Name=Y3250Y;alias=Y487Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1849;ao=18;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9750T;aa_name=p.Y3250Y;hgvs_nt=NC_045512.2:g.9750C>T;hgvs_aa=YP_009724389.1:p.Tyr3250Tyr;hgvs_alias=YP_009724389.1:Tyr487Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0096411355115158;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10029	10029	.	+	.	ID=ID_88;Name=T3255I;alias=T492I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1866;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9764T;aa_name=p.T3255I;hgvs_nt=NC_045512.2:g.9764C>T;hgvs_aa=YP_009724389.1:p.Thr3255Ile;hgvs_alias=YP_009724389.1:Thr492Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10198	10198	.	+	.	ID=ID_89;Name=D3311D;alias=D48D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1863;dp=1863;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C9933T;aa_name=p.D3311D;hgvs_nt=NC_045512.2:g.9933C>T;hgvs_aa=YP_009724389.1:p.Asp3311Asp;hgvs_alias=YP_009724389.1:Asp48Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10279	10279	.	+	.	ID=ID_90;Name=L3338L;alias=L75L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1850;ao=18;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C10014T;aa_name=p.L3338L;hgvs_nt=NC_045512.2:g.10014C>T;hgvs_aa=YP_009724389.1:p.Leu3338Leu;hgvs_alias=YP_009724389.1:Leu75Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009635974304068522;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10323	10323	.	+	.	ID=ID_91;Name=K3353R;alias=K90R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1812;ao=55;dp=1867;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A10058G;aa_name=p.K3353R;hgvs_nt=NC_045512.2:g.10058A>G;hgvs_aa=YP_009724389.1:p.Lys3353Arg;hgvs_alias=YP_009724389.1:Lys90Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02945902517407606;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10369	10369	.	+	.	ID=ID_92;Name=R3368R;alias=R105R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1853;ao=14;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C10104T;aa_name=p.R3368R;hgvs_nt=NC_045512.2:g.10104C>T;hgvs_aa=YP_009724389.1:p.Arg3368Arg;hgvs_alias=YP_009724389.1:Arg105Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007498660953401178;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10447	10447	.	+	.	ID=ID_93;Name=P3395H;alias=P132H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1869;dp=1870;sample_size=1924;Reference_seq=GCC;Variant_seq=ACA;nt_name=g.GCC10182_10184ACA;aa_name=p.P3395H;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Pro3395His;hgvs_alias=YP_009724389.1:Pro132His;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994652406417113;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10507	10507	.	+	.	ID=ID_94;Name=N3414N;alias=N151N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1854;ao=16;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C10242T;aa_name=p.N3414N;hgvs_nt=NC_045512.2:g.10242C>T;hgvs_aa=YP_009724389.1:p.Asn3414Asn;hgvs_alias=YP_009724389.1:Asn151Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008556149732620321;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10861	10861	.	+	.	ID=ID_95;Name=K3532K;alias=K269K;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1853;ao=16;dp=1869;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A10596G;aa_name=p.K3532K;hgvs_nt=NC_045512.2:g.10596A>G;hgvs_aa=YP_009724389.1:p.Lys3532Lys;hgvs_alias=YP_009724389.1:Lys269Lys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008560727661851257;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	10969	10969	.	+	.	ID=ID_96;Name=F3568F;alias=F305F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1860;ao=10;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C10704T;aa_name=p.F3568F;hgvs_nt=NC_045512.2:g.10704C>T;hgvs_aa=YP_009724389.1:p.Phe3568Phe;hgvs_alias=YP_009724389.1:Phe305Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11020	11020	.	+	.	ID=ID_97;Name=L3585L;alias=L16L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1837;ao=33;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C10755T;aa_name=p.L3585L;hgvs_nt=NC_045512.2:g.10755C>T;hgvs_aa=YP_009724389.1:p.Leu3585Leu;hgvs_alias=YP_009724389.1:Leu16Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01764705882352941;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11042	11042	.	+	.	ID=ID_98;Name=V3593F;alias=V24F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=780;ao=1090;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G10777T;aa_name=p.V3593F;hgvs_nt=NC_045512.2:g.10777G>T;hgvs_aa=YP_009724389.1:p.Val3593Phe;hgvs_alias=YP_009724389.1:Val24Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5828877005347594;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11083	11083	.	+	.	ID=ID_99;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1836;ao=31;dp=1868;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016595289079229122;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11173	11173	.	+	.	ID=ID_100;Name=L3636L;alias=L67L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1857;ao=13;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C10908T;aa_name=p.L3636L;hgvs_nt=NC_045512.2:g.10908C>T;hgvs_aa=YP_009724389.1:p.Leu3636Leu;hgvs_alias=YP_009724389.1:Leu67Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006951871657754011;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11287	11287	.	+	.	ID=ID_101;Name=S3675del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=3676del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11287	11287	.	+	.	ID=ID_101;Name=3676del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11287	11287	.	+	.	ID=ID_101;Name=F3677del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,3676del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11537	11537	.	+	.	ID=ID_102;Name=I3758V;alias=I189V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1841;ao=12;dp=1853;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A11272G;aa_name=p.I3758V;hgvs_nt=NC_045512.2:g.11272A>G;hgvs_aa=YP_009724389.1:p.Ile3758Val;hgvs_alias=YP_009724389.1:Ile189Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0064759848893685915;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11601	11601	.	+	.	ID=ID_103;Name=I3779T;alias=I210T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1848;ao=15;dp=1863;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T11336C;aa_name=p.I3779T;hgvs_nt=NC_045512.2:g.11336T>C;hgvs_aa=YP_009724389.1:p.Ile3779Thr;hgvs_alias=YP_009724389.1:Ile210Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008051529790660225;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11727	11727	.	+	.	ID=ID_104;Name=R3821K;alias=R252K;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=887;ao=976;dp=1863;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G11462A;aa_name=p.R3821K;hgvs_nt=NC_045512.2:g.11462G>A;hgvs_aa=YP_009724389.1:p.Arg3821Lys;hgvs_alias=YP_009724389.1:Arg252Lys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5238862050456253;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11747	11747	.	+	.	ID=ID_105;Name=L3828L;alias=L259L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1751;ao=111;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C11482T;aa_name=p.L3828L;hgvs_nt=NC_045512.2:g.11482C>T;hgvs_aa=YP_009724389.1:p.Leu3828Leu;hgvs_alias=YP_009724389.1:Leu259Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.059613319011815255;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11750	11750	.	+	.	ID=ID_106;Name=L3829F;alias=L260F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1835;ao=27;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C11485T;aa_name=p.L3829F;hgvs_nt=NC_045512.2:g.11485C>T;hgvs_aa=YP_009724389.1:p.Leu3829Phe;hgvs_alias=YP_009724389.1:Leu260Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014500537056928034;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11866	11866	.	+	.	ID=ID_107;Name=C3867C;alias=C8C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1855;ao=15;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C11601T;aa_name=p.C3867C;hgvs_nt=NC_045512.2:g.11601C>T;hgvs_aa=YP_009724389.1:p.Cys3867Cys;hgvs_alias=YP_009724389.1:Cys8Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008021390374331552;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11956	11956	.	+	.	ID=ID_108;Name=D3897D;alias=D38D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1799;ao=70;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C11691T;aa_name=p.D3897D;hgvs_nt=NC_045512.2:g.11691C>T;hgvs_aa=YP_009724389.1:p.Asp3897Asp;hgvs_alias=YP_009724389.1:Asp38Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03745318352059925;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	11986	11986	.	+	.	ID=ID_109;Name=A3907A;alias=A48A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1809;ao=61;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C11721T;aa_name=p.A3907A;hgvs_nt=NC_045512.2:g.11721C>T;hgvs_aa=YP_009724389.1:p.Ala3907Ala;hgvs_alias=YP_009724389.1:Ala48Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.032620320855614976;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12397	12397	.	+	.	ID=ID_110;Name=A4044A;alias=A102A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1853;ao=16;dp=1869;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A12132G;aa_name=p.A4044A;hgvs_nt=NC_045512.2:g.12132A>G;hgvs_aa=YP_009724389.1:p.Ala4044Ala;hgvs_alias=YP_009724389.1:Ala102Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008560727661851257;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12467	12467	.	+	.	ID=ID_111;Name=A4068S;alias=A126S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1857;ao=13;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G12202T;aa_name=p.A4068S;hgvs_nt=NC_045512.2:g.12202G>T;hgvs_aa=YP_009724389.1:p.Ala4068Ser;hgvs_alias=YP_009724389.1:Ala126Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006951871657754011;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12513	12513	.	+	.	ID=ID_112;Name=T4083M;alias=T141M;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1756;ao=106;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12248T;aa_name=p.T4083M;hgvs_nt=NC_045512.2:g.12248C>T;hgvs_aa=YP_009724389.1:p.Thr4083Met;hgvs_alias=YP_009724389.1:Thr141Met;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05692803437164339;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12651	12651	.	+	.	ID=ID_113;Name=T4129I;alias=T187I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=;ro=1816;ao=48;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12386T;aa_name=p.T4129I;hgvs_nt=NC_045512.2:g.12386C>T;hgvs_aa=YP_009724389.1:p.Thr4129Ile;hgvs_alias=YP_009724389.1:Thr187Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02575107296137339;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12730	12730	.	+	.	ID=ID_114;Name=A4155A;alias=A15A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1843;ao=20;dp=1863;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T12465A;aa_name=p.A4155A;hgvs_nt=NC_045512.2:g.12465T>A;hgvs_aa=YP_009724389.1:p.Ala4155Ala;hgvs_alias=YP_009724389.1:Ala15Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010735373054213635;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12756	12756	.	+	.	ID=ID_115;Name=T4164I;alias=T24I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1852;ao=11;dp=1863;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12491T;aa_name=p.T4164I;hgvs_nt=NC_045512.2:g.12491C>T;hgvs_aa=YP_009724389.1:p.Thr4164Ile;hgvs_alias=YP_009724389.1:Thr24Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005904455179817499;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12789	12789	.	+	.	ID=ID_116;Name=T4175I;alias=T35I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=116;ao=1753;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12524T;aa_name=p.T4175I;hgvs_nt=NC_045512.2:g.12524C>T;hgvs_aa=YP_009724389.1:p.Thr4175Ile;hgvs_alias=YP_009724389.1:Thr35Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9379347244515784;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12809	12809	.	+	.	ID=ID_117;Name=L4182F;alias=L42F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1858;ao=12;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12544T;aa_name=p.L4182F;hgvs_nt=NC_045512.2:g.12544C>T;hgvs_aa=YP_009724389.1:p.Leu4182Phe;hgvs_alias=YP_009724389.1:Leu42Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006417112299465241;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12815	12815	.	+	.	ID=ID_118;Name=L4184L;alias=L44L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=781;ao=1089;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12550T;aa_name=p.L4184L;hgvs_nt=NC_045512.2:g.12550C>T;hgvs_aa=YP_009724389.1:p.Leu4184Leu;hgvs_alias=YP_009724389.1:Leu44Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5823529411764706;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12880	12880	.	+	.	ID=ID_119;Name=I4205I;alias=I65I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12615T;aa_name=p.I4205I;hgvs_nt=NC_045512.2:g.12615C>T;hgvs_aa=YP_009724389.1:p.Ile4205Ile;hgvs_alias=YP_009724389.1:Ile65Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12928	12928	.	+	.	ID=ID_120;Name=K4221K;alias=K81K;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1847;ao=23;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A12663G;aa_name=p.K4221K;hgvs_nt=NC_045512.2:g.12663A>G;hgvs_aa=YP_009724389.1:p.Lys4221Lys;hgvs_alias=YP_009724389.1:Lys81Lys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01229946524064171;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	12970	12970	.	+	.	ID=ID_121;Name=N4235N;alias=N95N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1819;ao=51;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12705T;aa_name=p.N4235N;hgvs_nt=NC_045512.2:g.12705C>T;hgvs_aa=YP_009724389.1:p.Asn4235Asn;hgvs_alias=YP_009724389.1:Asn95Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02727272727272727;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	13019	13019	.	+	.	ID=ID_122;Name=L4252L;alias=L112L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=1820;ao=50;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C12754T;aa_name=p.L4252L;hgvs_nt=NC_045512.2:g.12754C>T;hgvs_aa=YP_009724389.1:p.Leu4252Leu;hgvs_alias=YP_009724389.1:Leu112Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026737967914438502;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	13339	13339	.	+	.	ID=ID_123;Name=N4358N;alias=N105N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=;ro=781;ao=1087;dp=1868;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T13074C;aa_name=p.N4358N;hgvs_nt=NC_045512.2:g.13074T>C;hgvs_aa=YP_009724389.1:p.Asn4358Asn;hgvs_alias=YP_009724389.1:Asn105Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5819057815845824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	13627	13627	.	+	.	ID=ID_124;Name=D4455N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1741;ao=128;dp=1869;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G13363A;aa_name=p.D4455N;hgvs_nt=NC_045512.2:g.13363G>A;hgvs_aa=YP_009724389.1:p.Asp4455Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06848582129481005;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	13663	13663	.	+	.	ID=ID_125;Name=H4467N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1839;ao=31;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C13399A;aa_name=p.H4467N;hgvs_nt=NC_045512.2:g.13399C>A;hgvs_aa=YP_009724389.1:p.His4467Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.016577540106951873;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	13829	13829	.	+	.	ID=ID_126;Name=A4522V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1852;ao=18;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13565T;aa_name=p.A4522V;hgvs_nt=NC_045512.2:g.13565C>T;hgvs_aa=YP_009724389.1:p.Ala4522Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009625668449197862;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14085	14085	.	+	.	ID=ID_127;Name=N4607N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1801;ao=69;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13821T;aa_name=p.N4607N;hgvs_nt=NC_045512.2:g.13821C>T;hgvs_aa=YP_009724389.1:p.Asn4607Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03689839572192513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14189	14189	.	+	.	ID=ID_128;Name=A4642V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1801;ao=69;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13925T;aa_name=p.A4642V;hgvs_nt=NC_045512.2:g.13925C>T;hgvs_aa=YP_009724389.1:p.Ala4642Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03689839572192513;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14334	14334	.	+	.	ID=ID_129;Name=C4690C;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1833;ao=37;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T14070C;aa_name=p.C4690C;hgvs_nt=NC_045512.2:g.14070T>C;hgvs_aa=YP_009724389.1:p.Cys4690Cys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.019786096256684493;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14408	14408	.	+	.	ID=ID_130;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14418	14418	.	+	.	ID=ID_131;Name=F4718F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T14154C;aa_name=p.F4718F;hgvs_nt=NC_045512.2:g.14154T>C;hgvs_aa=YP_009724389.1:p.Phe4718Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14634	14634	.	+	.	ID=ID_132;Name=V4790V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=71;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A14370G;aa_name=p.V4790V;hgvs_nt=NC_045512.2:g.14370A>G;hgvs_aa=YP_009724389.1:p.Val4790Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03796791443850268;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14856	14856	.	+	.	ID=ID_133;Name=V4864V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1850;ao=17;dp=1867;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A14592G;aa_name=p.V4864V;hgvs_nt=NC_045512.2:g.14592A>G;hgvs_aa=YP_009724389.1:p.Val4864Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009105516871987145;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	14889	14889	.	+	.	ID=ID_134;Name=Y4875Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1858;ao=10;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C14625T;aa_name=p.Y4875Y;hgvs_nt=NC_045512.2:g.14625C>T;hgvs_aa=YP_009724389.1:p.Tyr4875Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053533190578158455;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15026	15026	.	+	.	ID=ID_135;Name=A4921V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1856;ao=11;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C14762T;aa_name=p.A4921V;hgvs_nt=NC_045512.2:g.14762C>T;hgvs_aa=YP_009724389.1:p.Ala4921Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058918050348152114;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15451	15451	.	+	.	ID=ID_136;Name=G5063S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1086;ao=783;dp=1869;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G15187A;aa_name=p.G5063S;hgvs_nt=NC_045512.2:g.15187G>A;hgvs_aa=YP_009724389.1:p.Gly5063Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4189406099518459;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15656	15656	.	+	.	ID=ID_137;Name=T5131I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C15392T;aa_name=p.T5131I;hgvs_nt=NC_045512.2:g.15392C>T;hgvs_aa=YP_009724389.1:p.Thr5131Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15714	15714	.	+	.	ID=ID_138;Name=L5150L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C15450T;aa_name=p.L5150L;hgvs_nt=NC_045512.2:g.15450C>T;hgvs_aa=YP_009724389.1:p.Leu5150Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15738	15738	.	+	.	ID=ID_139;Name=F5158F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1095;ao=775;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C15474T;aa_name=p.F5158F;hgvs_nt=NC_045512.2:g.15474C>T;hgvs_aa=YP_009724389.1:p.Phe5158Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4144385026737968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15756	15756	.	+	.	ID=ID_140;Name=S5164S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=781;ao=1089;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T15492A;aa_name=p.S5164S;hgvs_nt=NC_045512.2:g.15492T>A;hgvs_aa=YP_009724389.1:p.Ser5164Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5823529411764706;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	15939	15939	.	+	.	ID=ID_141;Name=D5225D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1090;ao=780;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T15675C;aa_name=p.D5225D;hgvs_nt=NC_045512.2:g.15675T>C;hgvs_aa=YP_009724389.1:p.Asp5225Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41711229946524064;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	16342	16342	.	+	.	ID=ID_142;Name=S5360P;alias=S36P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1099;ao=771;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T16078C;aa_name=p.S5360P;hgvs_nt=NC_045512.2:g.16078T>C;hgvs_aa=YP_009724389.1:p.Ser5360Pro;hgvs_alias=YP_009724389.1:Ser36Pro;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4122994652406417;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	16878	16878	.	+	.	ID=ID_143;Name=T5538T;alias=T214T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1256;ao=613;dp=1869;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A16614T;aa_name=p.T5538T;hgvs_nt=NC_045512.2:g.16614A>T;hgvs_aa=YP_009724389.1:p.Thr5538Thr;hgvs_alias=YP_009724389.1:Thr214Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3279828785446763;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	16887	16887	.	+	.	ID=ID_144;Name=Y5541Y;alias=Y217Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1793;ao=76;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C16623T;aa_name=p.Y5541Y;hgvs_nt=NC_045512.2:g.16623C>T;hgvs_aa=YP_009724389.1:p.Tyr5541Tyr;hgvs_alias=YP_009724389.1:Tyr217Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04066345639379347;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	16983	16983	.	+	.	ID=ID_145;Name=I5573I;alias=I249I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1832;ao=18;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T16719A;aa_name=p.I5573I;hgvs_nt=NC_045512.2:g.16719T>A;hgvs_aa=YP_009724389.1:p.Ile5573Ile;hgvs_alias=YP_009724389.1:Ile249Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009625668449197862;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	16983	16983	.	+	.	ID=ID_145;Name=I5573I;alias=I249I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1832;ao=20;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T16719C;aa_name=p.I5573I;hgvs_nt=NC_045512.2:g.16719T>C;hgvs_aa=YP_009724389.1:p.Ile5573Ile;hgvs_alias=YP_009724389.1:Ile249Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0106951871657754;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	16985	16985	.	+	.	ID=ID_146;Name=T5574I;alias=T250I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1853;ao=17;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C16721T;aa_name=p.T5574I;hgvs_nt=NC_045512.2:g.16721C>T;hgvs_aa=YP_009724389.1:p.Thr5574Ile;hgvs_alias=YP_009724389.1:Thr250Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00909090909090909;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	17124	17124	.	+	.	ID=ID_147;Name=A5620A;alias=A296A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1786;ao=84;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T16860C;aa_name=p.A5620A;hgvs_nt=NC_045512.2:g.16860T>C;hgvs_aa=YP_009724389.1:p.Ala5620Ala;hgvs_alias=YP_009724389.1:Ala296Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044919786096256686;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	17268	17268	.	+	.	ID=ID_148;Name=D5668D;alias=D344D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T17004C;aa_name=p.D5668D;hgvs_nt=NC_045512.2:g.17004T>C;hgvs_aa=YP_009724389.1:p.Asp5668Asp;hgvs_alias=YP_009724389.1:Asp344Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	17410	17410	.	+	.	ID=ID_149;Name=R5716C;alias=R392C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=0;ao=1866;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C17146T;aa_name=p.R5716C;hgvs_nt=NC_045512.2:g.17146C>T;hgvs_aa=YP_009724389.1:p.Arg5716Cys;hgvs_alias=YP_009724389.1:Arg392Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	17562	17562	.	+	.	ID=ID_150;Name=R5766R;alias=R442R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1844;ao=26;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G17298T;aa_name=p.R5766R;hgvs_nt=NC_045512.2:g.17298G>T;hgvs_aa=YP_009724389.1:p.Arg5766Arg;hgvs_alias=YP_009724389.1:Arg442Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013903743315508022;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	17766	17766	.	+	.	ID=ID_151;Name=V5834V;alias=V510V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1856;ao=14;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C17502T;aa_name=p.V5834V;hgvs_nt=NC_045512.2:g.17502C>T;hgvs_aa=YP_009724389.1:p.Val5834Val;hgvs_alias=YP_009724389.1:Val510Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0074866310160427805;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	17859	17859	.	+	.	ID=ID_152;Name=Y5865Y;alias=Y541Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=;ro=1096;ao=774;dp=1870;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T17595C;aa_name=p.Y5865Y;hgvs_nt=NC_045512.2:g.17595T>C;hgvs_aa=YP_009724389.1:p.Tyr5865Tyr;hgvs_alias=YP_009724389.1:Tyr541Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.413903743315508;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18163	18163	.	+	.	ID=ID_153;Name=I5967V;alias=I42V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=0;ao=1869;dp=1869;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A17899G;aa_name=p.I5967V;hgvs_nt=NC_045512.2:g.17899A>G;hgvs_aa=YP_009724389.1:p.Ile5967Val;hgvs_alias=YP_009724389.1:Ile42Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18270	18270	.	+	.	ID=ID_154;Name=E6002D;alias=E77D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1851;ao=16;dp=1867;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A18006C;aa_name=p.E6002D;hgvs_nt=NC_045512.2:g.18006A>C;hgvs_aa=YP_009724389.1:p.Glu6002Asp;hgvs_alias=YP_009724389.1:Glu77Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00856989823245849;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18453	18453	.	+	.	ID=ID_155;Name=A6063A;alias=A138A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1781;ao=86;dp=1867;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T18189C;aa_name=p.A6063A;hgvs_nt=NC_045512.2:g.18189T>C;hgvs_aa=YP_009724389.1:p.Ala6063Ala;hgvs_alias=YP_009724389.1:Ala138Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.046063202999464384;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18483	18483	.	+	.	ID=ID_156;Name=H6073H;alias=H148H;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1857;ao=10;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18219T;aa_name=p.H6073H;hgvs_nt=NC_045512.2:g.18219C>T;hgvs_aa=YP_009724389.1:p.His6073His;hgvs_alias=YP_009724389.1:His148His;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005356186395286556;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18492	18492	.	+	.	ID=ID_157;Name=P6076P;alias=P151P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=167;ao=1701;dp=1868;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A18228G;aa_name=p.P6076P;hgvs_nt=NC_045512.2:g.18228A>G;hgvs_aa=YP_009724389.1:p.Pro6076Pro;hgvs_alias=YP_009724389.1:Pro151Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9105995717344754;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18555	18555	.	+	.	ID=ID_158;Name=D6097D;alias=D172D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1847;ao=20;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18291T;aa_name=p.D6097D;hgvs_nt=NC_045512.2:g.18291C>T;hgvs_aa=YP_009724389.1:p.Asp6097Asp;hgvs_alias=YP_009724389.1:Asp172Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010712372790573112;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18657	18657	.	+	.	ID=ID_159;Name=T6131T;alias=T206T;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1848;ao=20;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18393T;aa_name=p.T6131T;hgvs_nt=NC_045512.2:g.18393C>T;hgvs_aa=YP_009724389.1:p.Thr6131Thr;hgvs_alias=YP_009724389.1:Thr206Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010706638115631691;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18687	18687	.	+	.	ID=ID_160;Name=C6141C;alias=C216C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1818;ao=50;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18423T;aa_name=p.C6141C;hgvs_nt=NC_045512.2:g.18423C>T;hgvs_aa=YP_009724389.1:p.Cys6141Cys;hgvs_alias=YP_009724389.1:Cys216Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02676659528907923;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18703	18703	.	+	.	ID=ID_161;Name=D6147Y;alias=D222Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1849;ao=17;dp=1866;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G18439T;aa_name=p.D6147Y;hgvs_nt=NC_045512.2:g.18439G>T;hgvs_aa=YP_009724389.1:p.Asp6147Tyr;hgvs_alias=YP_009724389.1:Asp222Tyr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009110396570203644;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18738	18738	.	+	.	ID=ID_162;Name=F6158L;alias=F233L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1853;ao=15;dp=1868;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T18474A;aa_name=p.F6158L;hgvs_nt=NC_045512.2:g.18474T>A;hgvs_aa=YP_009724389.1:p.Phe6158Leu;hgvs_alias=YP_009724389.1:Phe233Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008029978586723769;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18826	18826	.	+	.	ID=ID_163;Name=V6188I;alias=V263I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1857;ao=13;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G18562A;aa_name=p.V6188I;hgvs_nt=NC_045512.2:g.18562G>A;hgvs_aa=YP_009724389.1:p.Val6188Ile;hgvs_alias=YP_009724389.1:Val263Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006951871657754011;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	18894	18894	.	+	.	ID=ID_164;Name=C6210C;alias=C285C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=889;ao=981;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18630T;aa_name=p.C6210C;hgvs_nt=NC_045512.2:g.18630C>T;hgvs_aa=YP_009724389.1:p.Cys6210Cys;hgvs_alias=YP_009724389.1:Cys285Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5245989304812835;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19018	19018	.	+	.	ID=ID_165;Name=P6252S;alias=P327S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18754T;aa_name=p.P6252S;hgvs_nt=NC_045512.2:g.18754C>T;hgvs_aa=YP_009724389.1:p.Pro6252Ser;hgvs_alias=YP_009724389.1:Pro327Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19032	19032	.	+	.	ID=ID_166;Name=D6256D;alias=D331D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1858;ao=12;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18768T;aa_name=p.D6256D;hgvs_nt=NC_045512.2:g.18768C>T;hgvs_aa=YP_009724389.1:p.Asp6256Asp;hgvs_alias=YP_009724389.1:Asp331Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006417112299465241;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19185	19185	.	+	.	ID=ID_167;Name=C6307C;alias=C382C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1795;ao=75;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18921T;aa_name=p.C6307C;hgvs_nt=NC_045512.2:g.18921C>T;hgvs_aa=YP_009724389.1:p.Cys6307Cys;hgvs_alias=YP_009724389.1:Cys382Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040106951871657755;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19186	19186	.	+	.	ID=ID_168;Name=L6308L;alias=L383L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1818;ao=52;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C18922T;aa_name=p.L6308L;hgvs_nt=NC_045512.2:g.18922C>T;hgvs_aa=YP_009724389.1:p.Leu6308Leu;hgvs_alias=YP_009724389.1:Leu383Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.027807486631016044;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19326	19326	.	+	.	ID=ID_169;Name=P6354P;alias=P429P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1095;ao=775;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A19062G;aa_name=p.P6354P;hgvs_nt=NC_045512.2:g.19062A>G;hgvs_aa=YP_009724389.1:p.Pro6354Pro;hgvs_alias=YP_009724389.1:Pro429Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4144385026737968;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19488	19488	.	+	.	ID=ID_170;Name=V6408V;alias=V483V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=;ro=1786;ao=84;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C19224T;aa_name=p.V6408V;hgvs_nt=NC_045512.2:g.19224C>T;hgvs_aa=YP_009724389.1:p.Val6408Val;hgvs_alias=YP_009724389.1:Val483Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.044919786096256686;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	19955	19955	.	+	.	ID=ID_171;Name=T6564I;alias=T112I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C19691T;aa_name=p.T6564I;hgvs_nt=NC_045512.2:g.19691C>T;hgvs_aa=YP_009724389.1:p.Thr6564Ile;hgvs_alias=YP_009724389.1:Thr112Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	20055	20055	.	+	.	ID=ID_172;Name=E6597E;alias=E145E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A19791G;aa_name=p.E6597E;hgvs_nt=NC_045512.2:g.19791A>G;hgvs_aa=YP_009724389.1:p.Glu6597Glu;hgvs_alias=YP_009724389.1:Glu145Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	20178	20178	.	+	.	ID=ID_173;Name=V6638V;alias=V186V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=;ro=1842;ao=27;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C19914T;aa_name=p.V6638V;hgvs_nt=NC_045512.2:g.19914C>T;hgvs_aa=YP_009724389.1:p.Val6638Val;hgvs_alias=YP_009724389.1:Val186Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014446227929373997;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	20930	20930	.	+	.	ID=ID_174;Name=T6889M;alias=T91M;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=;ro=1763;ao=105;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C20666T;aa_name=p.T6889M;hgvs_nt=NC_045512.2:g.20666C>T;hgvs_aa=YP_009724389.1:p.Thr6889Met;hgvs_alias=YP_009724389.1:Thr91Met;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05620985010706638;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21137	21137	.	+	.	ID=ID_175;Name=K6958R;alias=K160R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=;ro=1796;ao=67;dp=1863;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A20873G;aa_name=p.K6958R;hgvs_nt=NC_045512.2:g.20873A>G;hgvs_aa=YP_009724389.1:p.Lys6958Arg;hgvs_alias=YP_009724389.1:Lys160Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.035963499731615674;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21145	21145	.	+	.	ID=ID_176;Name=L6961F;alias=L163F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=;ro=1849;ao=15;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C20881T;aa_name=p.L6961F;hgvs_nt=NC_045512.2:g.20881C>T;hgvs_aa=YP_009724389.1:p.Leu6961Phe;hgvs_alias=YP_009724389.1:Leu163Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008047210300429184;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21575	21575	.	+	.	ID=ID_177;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1835;ao=22;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011847065158858373;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21575	21575	.	+	.	ID=ID_178;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1835;ao=22;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011847065158858373;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21575	21575	.	+	.	ID=ID_178;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1835;ao=22;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011847065158858373;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21575	21575	.	+	.	ID=ID_178;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1835;ao=22;dp=1857;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011847065158858373;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21602	21602	.	+	.	ID=ID_179;Name=Q14K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1845;ao=14;dp=1859;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C40A;aa_name=p.Q14K;hgvs_nt=NC_045512.2:g.40C>A;hgvs_aa=YP_009724390.1:p.Gln14Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007530930607853685;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21608	21608	.	+	.	ID=ID_180;Name=V16_N17insMPLF;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=782;ao=1065;dp=1850;sample_size=1924;Reference_seq=G;Variant_seq=GTCATGCCGCTGT;nt_name=g.47_48insCATGCCGCTGTT;aa_name=p.V16_N17insMPLF;hgvs_nt=NC_045512.2:g.47_48insCATGCCGCTGTT;hgvs_aa=YP_009724390.1:p.Val16_Asn17insMetProLeuPhe;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5756756756756757;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21618	21618	.	+	.	ID=ID_181;Name=TTR19ITT;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=771;dp=1851;sample_size=1924;Reference_seq=CAACCAG;Variant_seq=TAACCAG;nt_name=g.CAACCAG56_62TAACTAC;aa_name=p.TTR19ITT;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.ThrThrArg19IleThrThr;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4165316045380875;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21711	21711	.	+	.	ID=ID_182;Name=S50L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1043;dp=1819;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C149T;aa_name=p.S50L;hgvs_nt=NC_045512.2:g.149C>T;hgvs_aa=YP_009724390.1:p.Ser50Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5733919736118747;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21718	21718	.	+	.	ID=ID_183;Name=Q52H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1213;ao=609;dp=1822;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G156T;aa_name=p.Q52H;hgvs_nt=NC_045512.2:g.156G>T;hgvs_aa=YP_009724390.1:p.Gln52His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.33424807903402853;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=H69del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=V70del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21764	21764	.	+	.	ID=ID_184;Name=V70del;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1039;dp=1817;sample_size=1924;Reference_seq=ATACATG;Variant_seq=A;nt_name=g.204_209delACATGT;aa_name=p.H69_V70del;hgvs_nt=NC_045512.2:g.204_209del;hgvs_aa=YP_009724390.1:p.His69_Val70del;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=H69_V70del;multiaa_comb_mutation=H69del;alternate_frequency=0.5718216840946615;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21810	21810	.	+	.	ID=ID_185;Name=V83A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1059;ao=770;dp=1829;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T248C;aa_name=p.V83A;hgvs_nt=NC_045512.2:g.248T>C;hgvs_aa=YP_009724390.1:p.Val83Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42099507927829416;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21941	21941	.	+	.	ID=ID_186;Name=V127F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=778;ao=1089;dp=1867;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G379T;aa_name=p.V127F;hgvs_nt=NC_045512.2:g.379G>T;hgvs_aa=YP_009724390.1:p.Val127Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5832886984467059;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21987	21987	.	+	.	ID=ID_187;Name=G142_Y144delinsDV;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1844;dp=1860;sample_size=1924;Reference_seq=GTGTTTA;Variant_seq=ATGT;nt_name=g.GTGTTTA425_431ATGT;aa_name=p.G142_Y144delinsDV;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly142_Tyr144delinsAspVal;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9913978494623656;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21998	21998	.	+	.	ID=ID_188;Name=H146Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1090;ao=35;dp=1866;sample_size=1924;Reference_seq=CAC;Variant_seq=AAA;nt_name=g.C438A;aa_name=p.H146Q;hgvs_nt=NC_045512.2:g.438C>A;hgvs_aa=YP_009724390.1:p.His146Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.018756698821007504;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	21998	21998	.	+	.	ID=ID_189;Name=H146K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1090;ao=733;dp=1866;sample_size=1924;Reference_seq=CAC;Variant_seq=CAA;nt_name=g.CAC436_438AAA;aa_name=p.H146K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.His146Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3928188638799571;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22032	22032	.	+	.	ID=ID_190;Name=F157L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=443;ao=1089;dp=1867;sample_size=1924;Reference_seq=TCA;Variant_seq=CAG;nt_name=g.C471A;aa_name=p.F157L;hgvs_nt=NC_045512.2:g.471C>A;hgvs_aa=YP_009724390.1:p.Phe157Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5832886984467059;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.06.28.449914;citation=Choi et al. (2021);comb_mutation=P681R;function_description=Neutralization efficiency (ID50) against A.23.1-v1 reduced 1.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22032	22032	.	+	.	ID=ID_190;Name=F157L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=443;ao=1089;dp=1867;sample_size=1924;Reference_seq=TCA;Variant_seq=CAG;nt_name=g.C471A;aa_name=p.F157L;hgvs_nt=NC_045512.2:g.471C>A;hgvs_aa=YP_009724390.1:p.Phe157Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5832886984467059;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.06.28.449914;citation=Choi et al. (2021);comb_mutation=P681R;function_description=Neutralization efficiency (ID50) against A.23.1-v1 reduced 1.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22032	22032	.	+	.	ID=ID_191;Name=FR157SG;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=443;ao=335;dp=1867;sample_size=1924;Reference_seq=TCA;Variant_seq=TAA;nt_name=g.TCA470_472CAG;aa_name=p.FR157SG;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.PheArg157SerGly;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.17943224424209964;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22101	22101	.	+	.	ID=ID_192;Name=E180V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1847;ao=17;dp=1864;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A539T;aa_name=p.E180V;hgvs_nt=NC_045512.2:g.539A>T;hgvs_aa=YP_009724390.1:p.Glu180Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.009120171673819743;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22109	22109	.	+	.	ID=ID_193;Name=Q183E;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1095;ao=770;dp=1865;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C547G;aa_name=p.Q183E;hgvs_nt=NC_045512.2:g.547C>G;hgvs_aa=YP_009724390.1:p.Gln183Glu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4128686327077748;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22111	22111	.	+	.	ID=ID_194;Name=Q183H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1851;ao=14;dp=1865;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G549T;aa_name=p.Q183H;hgvs_nt=NC_045512.2:g.549G>T;hgvs_aa=YP_009724390.1:p.Gln183His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007506702412868633;function_category=immunosuppression variant emergence;source=https://doi.org/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=nan;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22194	22194	.	+	.	ID=ID_195;Name=V213E;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1089;dp=1867;sample_size=1924;Reference_seq=ATTTAGT;Variant_seq=TAGG;nt_name=g.T638A;aa_name=p.V213E;hgvs_nt=NC_045512.2:g.638T>A;hgvs_aa=YP_009724390.1:p.Val213Glu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5832886984467059;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22194	22194	.	+	.	ID=ID_196;Name=N211_V213delinsIG;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=772;dp=1867;sample_size=1924;Reference_seq=ATTTAGT;Variant_seq=ATTTAGA;nt_name=g.ATTTAGT632_638TAGG;aa_name=p.N211_V213delinsIG;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Asn211_Val213delinsIleGly;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4134975897161221;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22204	22204	.	+	.	ID=ID_197;Name=R214_D215insYRR;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1847;ao=16;dp=1867;sample_size=1924;Reference_seq=T;Variant_seq=TTACAGGAGG;nt_name=g.642_643insTACAGGAGG;aa_name=p.R214_D215insYRR;hgvs_nt=NC_045512.2:g.642_643insTACAGGAGG;hgvs_aa=YP_009724390.1:p.Arg214_Asp215insTyrArgArg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00856989823245849;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22208	22208	.	+	.	ID=ID_198;Name=L216F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=776;ao=1090;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C646T;aa_name=p.L216F;hgvs_nt=NC_045512.2:g.646C>T;hgvs_aa=YP_009724390.1:p.Leu216Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5838243170862346;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22295	22295	.	+	.	ID=ID_199;Name=H245N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=769;ao=1088;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C733A;aa_name=p.H245N;hgvs_nt=NC_045512.2:g.733C>A;hgvs_aa=YP_009724390.1:p.His245Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5830653804930332;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22304	22304	.	+	.	ID=ID_200;Name=Y248H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1829;ao=37;dp=1866;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T742C;aa_name=p.Y248H;hgvs_nt=NC_045512.2:g.742T>C;hgvs_aa=YP_009724390.1:p.Tyr248His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01982851018220793;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.06.455491;citation=Schmidt et al. (2021);comb_mutation=nan;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22317	22317	.	+	.	ID=ID_201;Name=G252V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1099;ao=768;dp=1867;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G755T;aa_name=p.G252V;hgvs_nt=NC_045512.2:g.755G>T;hgvs_aa=YP_009724390.1:p.Gly252Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4113551151580075;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22353	22353	.	+	.	ID=ID_202;Name=A264D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=780;ao=1088;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C791A;aa_name=p.A264D;hgvs_nt=NC_045512.2:g.791C>A;hgvs_aa=YP_009724390.1:p.Ala264Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.582441113490364;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22480	22480	.	+	.	ID=ID_203;Name=T307I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1250;ao=13;dp=1863;sample_size=1924;Reference_seq=CAC;Variant_seq=TAT;nt_name=g.CAC918_920TAT;aa_name=p.T307I;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Thr307Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006977992485238862;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22480	22480	.	+	.	ID=ID_204;Name=F306F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1250;ao=599;dp=1863;sample_size=1924;Reference_seq=CAC;Variant_seq=TAC;nt_name=g.C918T;aa_name=p.F306F;hgvs_nt=NC_045512.2:g.918C>T;hgvs_aa=YP_009724390.1:p.Phe306Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3215244229736983;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22556	22556	.	+	.	ID=ID_205;Name=I332V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=769;ao=1090;dp=1859;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A994G;aa_name=p.I332V;hgvs_nt=NC_045512.2:g.994A>G;hgvs_aa=YP_009724390.1:p.Ile332Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5863367401828941;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22570	22570	.	+	.	ID=ID_206;Name=C336C;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1721;ao=138;dp=1859;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1008T;aa_name=p.C336C;hgvs_nt=NC_045512.2:g.1008C>T;hgvs_aa=YP_009724390.1:p.Cys336Cys;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07423345884884347;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22577	22577	.	+	.	ID=ID_207;Name=G339H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1860;dp=1860;sample_size=1924;Reference_seq=GG;Variant_seq=CA;nt_name=g.GG1015_1016CA;aa_name=p.G339H;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly339His;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22577	22577	.	+	.	ID=ID_207;Name=G339H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1860;dp=1860;sample_size=1924;Reference_seq=GG;Variant_seq=CA;nt_name=g.GG1015_1016CA;aa_name=p.G339H;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly339His;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22577	22577	.	+	.	ID=ID_207;Name=G339H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1860;dp=1860;sample_size=1924;Reference_seq=GG;Variant_seq=CA;nt_name=g.GG1015_1016CA;aa_name=p.G339H;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly339His;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22577	22577	.	+	.	ID=ID_207;Name=G339H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1860;dp=1860;sample_size=1924;Reference_seq=GG;Variant_seq=CA;nt_name=g.GG1015_1016CA;aa_name=p.G339H;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly339His;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22599	22599	.	+	.	ID=ID_208;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1085;ao=771;dp=1861;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41429339065018805;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22624	22624	.	+	.	ID=ID_209;Name=N354N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1838;ao=24;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1062T;aa_name=p.N354N;hgvs_nt=NC_045512.2:g.1062C>T;hgvs_aa=YP_009724390.1:p.Asn354Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01288936627282492;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22629	22629	.	+	.	ID=ID_210;Name=K356T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=766;ao=1096;dp=1862;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1067C;aa_name=p.K356T;hgvs_nt=NC_045512.2:g.1067A>C;hgvs_aa=YP_009724390.1:p.Lys356Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5886143931256713;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.14 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22629	22629	.	+	.	ID=ID_210;Name=K356T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=766;ao=1096;dp=1862;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1067C;aa_name=p.K356T;hgvs_nt=NC_045512.2:g.1067A>C;hgvs_aa=YP_009724390.1:p.Lys356Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5886143931256713;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.14 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22679	22679	.	+	.	ID=ID_211;Name=S373P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1856;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1117C;aa_name=p.S373P;hgvs_nt=NC_045512.2:g.1117T>C;hgvs_aa=YP_009724390.1:p.Ser373Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994614970382337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1128/mBio.02707-20;citation=Long et al. (2020);comb_mutation=nan;function_description=Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22679	22679	.	+	.	ID=ID_211;Name=S373P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1856;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1117C;aa_name=p.S373P;hgvs_nt=NC_045512.2:g.1117T>C;hgvs_aa=YP_009724390.1:p.Ser373Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994614970382337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1128/mBio.02707-20;citation=Long et al. (2020);comb_mutation=nan;function_description=Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22679	22679	.	+	.	ID=ID_212;Name=S373P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1856;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1117C;aa_name=p.S373P;hgvs_nt=NC_045512.2:g.1117T>C;hgvs_aa=YP_009724390.1:p.Ser373Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994614970382337;function_category=transmissibility;source=https://doi.org/10.47326/ocsat.dashboard.2021.1.0;citation=nan et al. (2021);comb_mutation=E484A;function_description=On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22679	22679	.	+	.	ID=ID_212;Name=S373P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1856;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1117C;aa_name=p.S373P;hgvs_nt=NC_045512.2:g.1117T>C;hgvs_aa=YP_009724390.1:p.Ser373Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994614970382337;function_category=transmissibility;source=https://doi.org/10.47326/ocsat.dashboard.2021.1.0;citation=nan et al. (2021);comb_mutation=E484A;function_description=On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22686	22686	.	+	.	ID=ID_213;Name=ST375FA;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1855;dp=1859;sample_size=1924;Reference_seq=CCA;Variant_seq=TCG;nt_name=g.CCA1124_1126TCG;aa_name=p.ST375FA;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr375PheAla;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9978483055406132;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22770	22770	.	+	.	ID=ID_214;Name=R403K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=763;ao=1090;dp=1853;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G1208A;aa_name=p.R403K;hgvs_nt=NC_045512.2:g.1208G>A;hgvs_aa=YP_009724390.1:p.Arg403Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5882352941176471;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_215;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_215;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_215;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_215;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_216;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=N501Y,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_216;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=N501Y,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_216;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=N501Y,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22786	22786	.	+	.	ID=ID_216;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=N501Y,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_218;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=E484A;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_218;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=E484A;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_218;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=E484A;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_218;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=E484A;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_218;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=E484A;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_219;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_219;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_219;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_219;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_219;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=No detectable fold drop in IC50 of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P22A-1D1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes no detectable change in KD value for antibody binding of P5A-1D2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 1.5 fold decrease in KD value of antibody binding of ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 1.5 fold decrease in KD value of antibody binding of ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 1.5 fold decrease in KD value of antibody binding of ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 1.5 fold decrease in KD value of antibody binding of ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=Causes 1.5 fold decrease in KD value of antibody binding of ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=1.1 fold drop in IC50 of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=1.1 fold drop in IC50 of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=1.1 fold drop in IC50 of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=1.1 fold drop in IC50 of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41467-021-24514-w;citation=Zhang et al. (2021);comb_mutation=nan;function_description=1.1 fold drop in IC50 of P2C-1F11.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=nan;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=nan;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=nan;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=nan;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_217;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=nan;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_220;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22813	22813	.	+	.	ID=ID_221;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.07.21.214759;citation=Weisblum et al. (2020);comb_mutation=nan;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.07.21.214759;citation=Weisblum et al. (2020);comb_mutation=nan;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.07.21.214759;citation=Weisblum et al. (2020);comb_mutation=nan;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.07.21.214759;citation=Weisblum et al. (2020);comb_mutation=nan;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.07.21.214759;citation=Weisblum et al. (2020);comb_mutation=nan;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.07.21.214759;citation=Weisblum et al. (2020);comb_mutation=nan;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.04.30.441434;citation=Tandel et al. (2021);comb_mutation=nan;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.04.30.441434;citation=Tandel et al. (2021);comb_mutation=nan;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.04.30.441434;citation=Tandel et al. (2021);comb_mutation=nan;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.04.30.441434;citation=Tandel et al. (2021);comb_mutation=nan;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.04.30.441434;citation=Tandel et al. (2021);comb_mutation=nan;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.04.30.441434;citation=Tandel et al. (2021);comb_mutation=nan;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=nan;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=nan;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=nan;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=nan;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=nan;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_222;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=nan;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_223;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_223;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_223;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_223;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_223;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22882	22882	.	+	.	ID=ID_223;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1857;dp=1857;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22893	22893	.	+	.	ID=ID_224;Name=KVG444TPS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=24;dp=1857;sample_size=1924;Reference_seq=AGGTTG;Variant_seq=ATCCTA;nt_name=g.AGGTTG1331_1336CGCCTA;aa_name=p.KVG444TPS;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.LysValGly444ThrProSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012924071082390954;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22893	22893	.	+	.	ID=ID_225;Name=KVG444NPS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=15;dp=1857;sample_size=1924;Reference_seq=AGGTTG;Variant_seq=CGCCTA;nt_name=g.GGTTG1332_1336TCCTA;aa_name=p.KVG444NPS;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.LysValGly444AsnProSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008077544426494346;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22893	22893	.	+	.	ID=ID_226;Name=VG445HS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1076;dp=1857;sample_size=1924;Reference_seq=AGGTTG;Variant_seq=AGCATA;nt_name=g.GTTG1333_1336CATA;aa_name=p.VG445HS;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.ValGly445HisSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5794291868605277;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22893	22893	.	+	.	ID=ID_227;Name=VG445PS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=736;dp=1857;sample_size=1924;Reference_seq=AGGTTG;Variant_seq=AGCCTA;nt_name=g.GTTG1333_1336CCTA;aa_name=p.VG445PS;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.ValGly445ProSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3963381798599892;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=nan;function_description=Escape variant 95% appearance in 2 passages against Regeneron monoclonal antibody RGN10934 @ 50ug/mL;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=nan;function_description=Escape variant 95% appearance in 2 passages against Regeneron monoclonal antibody RGN10934 @ 50ug/mL;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-07 nd moderately resistant to SARS2-16 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-07 nd moderately resistant to SARS2-16 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 2 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 2 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.06.455491;citation=Schmidt et al. (2021);comb_mutation=nan;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.06.455491;citation=Schmidt et al. (2021);comb_mutation=nan;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22910	22910	.	+	.	ID=ID_228;Name=N450D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=686;ao=1172;dp=1858;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1348G;aa_name=p.N450D;hgvs_nt=NC_045512.2:g.1348A>G;hgvs_aa=YP_009724390.1:p.Asn450Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6307857911733046;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Wuhan-Hu-1 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.32 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=D614G;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=D614G;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=D614G;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=D614G;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=D614G;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=D614G;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~1.7-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferriera et al. (2021);comb_mutation=nan;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferriera et al. (2021);comb_mutation=nan;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferriera et al. (2021);comb_mutation=nan;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferriera et al. (2021);comb_mutation=nan;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferriera et al. (2021);comb_mutation=nan;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferriera et al. (2021);comb_mutation=nan;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistically significant, but error bars say otherwise in Figure 4];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.03.07.21252647;citation=Deng et al. (2021);comb_mutation=nan;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.03.07.21252647;citation=Deng et al. (2021);comb_mutation=nan;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.03.07.21252647;citation=Deng et al. (2021);comb_mutation=nan;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.03.07.21252647;citation=Deng et al. (2021);comb_mutation=nan;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.03.07.21252647;citation=Deng et al. (2021);comb_mutation=nan;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=trafficking;source=https://doi.org/10.1101/2021.03.07.21252647;citation=Deng et al. (2021);comb_mutation=nan;function_description=We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=nan;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=nan;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=nan;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=nan;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=nan;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=nan;function_description=Observed ~2x decrease on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.31.437925;citation=McCallum et al. (2021);comb_mutation=nan;function_description=10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1016/j.chom.2021.06.006;citation=Motozono et al. (2021);comb_mutation=nan;function_description=This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1016/j.chom.2021.06.006;citation=Motozono et al. (2021);comb_mutation=nan;function_description=This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1016/j.chom.2021.06.006;citation=Motozono et al. (2021);comb_mutation=nan;function_description=This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1016/j.chom.2021.06.006;citation=Motozono et al. (2021);comb_mutation=nan;function_description=This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1016/j.chom.2021.06.006;citation=Motozono et al. (2021);comb_mutation=nan;function_description=This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1016/j.chom.2021.06.006;citation=Motozono et al. (2021);comb_mutation=nan;function_description=This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=D614G;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_230;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=D614G;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferreira et al. (2021);comb_mutation=nan;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferreira et al. (2021);comb_mutation=nan;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferreira et al. (2021);comb_mutation=nan;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferreira et al. (2021);comb_mutation=nan;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferreira et al. (2021);comb_mutation=nan;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.05.08.443253;citation=Ferreira et al. (2021);comb_mutation=nan;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_231;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_231;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_231;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_231;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_231;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_231;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=N501Y;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_229;Name=L452R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=1077;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=TG;nt_name=g.T1355G;aa_name=p.L452R;hgvs_nt=NC_045512.2:g.1355T>G;hgvs_aa=YP_009724390.1:p.Leu452Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5802801724137931;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22916	22916	.	+	.	ID=ID_232;Name=L452W;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=459;ao=319;dp=1856;sample_size=1924;Reference_seq=CT;Variant_seq=CG;nt_name=g.CT1354_1355TG;aa_name=p.L452W;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Leu452Trp;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.171875;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22926	22926	.	+	.	ID=ID_233;Name=L455S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=839;ao=1019;dp=1858;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1364C;aa_name=p.L455S;hgvs_nt=NC_045512.2:g.1364T>C;hgvs_aa=YP_009724390.1:p.Leu455Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5484391819160388;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.45 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=282;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TTTA;nt_name=g.T1366C;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1366T>C;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1518578352180937;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=282;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TTTA;nt_name=g.T1366C;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1366T>C;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1518578352180937;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=282;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TTTA;nt_name=g.T1366C;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1366T>C;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1518578352180937;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=282;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TTTA;nt_name=g.T1366C;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1366T>C;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1518578352180937;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=282;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TTTA;nt_name=g.T1366C;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1366T>C;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1518578352180937;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=282;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TTTA;nt_name=g.T1366C;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1366T>C;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1518578352180937;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=91;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TCTT;nt_name=g.T1368A;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1368T>A;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04900376952073236;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=91;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TCTT;nt_name=g.T1368A;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1368T>A;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04900376952073236;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=91;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TCTT;nt_name=g.T1368A;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1368T>A;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04900376952073236;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=91;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TCTT;nt_name=g.T1368A;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1368T>A;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04900376952073236;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=91;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TCTT;nt_name=g.T1368A;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1368T>A;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04900376952073236;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_234;Name=F456L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=91;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=TCTT;nt_name=g.T1368A;aa_name=p.F456L;hgvs_nt=NC_045512.2:g.1368T>A;hgvs_aa=YP_009724390.1:p.Phe456Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04900376952073236;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=This double substitution reduces neutralization by RBD-specific mAbs from different clusters,   specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.  For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                    just below the level required to calculate an IC50 value.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_235;Name=LF455FL;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=49;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=GCTT;nt_name=g.GT1365_1366TC;aa_name=p.LF455FL;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.LeuPhe455PheLeu;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.026386645126548196;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22927	22927	.	+	.	ID=ID_235;Name=LF455FL;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=342;dp=1857;sample_size=1924;Reference_seq=GTTT;Variant_seq=GTTA;nt_name=g.GTTT1365_1368TTTA;aa_name=p.LF455FL;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.LeuPhe455PheLeu;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1841680129240711;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1078;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=A;nt_name=g.T1380A;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>A;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5798816568047337;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22942	22942	.	+	.	ID=ID_236;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=781;dp=1859;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.42011834319526625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1038/s41586-020-2852-1;citation=Barnes et al. (2020);comb_mutation=nan;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with C102, C105 and C144 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~50x binding against this isolated mutation. Estesevimab lost ~8x binding against this isolated mutation. Sotrovimab lost ~30x binding against this isolated mutation. Tixagevimab lost ~15x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Resistent to some class 1 (Spike 'up' conformation) antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22986	22986	.	+	.	ID=ID_237;Name=A475V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1787;ao=75;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1424T;aa_name=p.A475V;hgvs_nt=NC_045512.2:g.1424C>T;hgvs_aa=YP_009724390.1:p.Ala475Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.040279269602577876;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.03.367391;citation=Gaebler et al. (2021);comb_mutation=nan;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22992	22992	.	+	.	ID=ID_238;Name=ST477NK;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1818;dp=1858;sample_size=1924;Reference_seq=GCAC;Variant_seq=ACAA;nt_name=g.GCAC1430_1433ACAA;aa_name=p.ST477NK;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr477AsnLys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9784714747039828;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	22992	22992	.	+	.	ID=ID_239;Name=ST477NR;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=35;dp=1858;sample_size=1924;Reference_seq=GCAC;Variant_seq=ACAG;nt_name=g.GCAC1430_1433ACAG;aa_name=p.ST477NR;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr477AsnArg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01883745963401507;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23005	23005	.	+	.	ID=ID_240;Name=N481K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=728;ao=1065;dp=1854;sample_size=1924;Reference_seq=TGGTGTTG;Variant_seq=AGGTA;nt_name=g.T1443A;aa_name=p.N481K;hgvs_nt=NC_045512.2:g.1443T>A;hgvs_aa=YP_009724390.1:p.Asn481Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5744336569579288;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23005	23005	.	+	.	ID=ID_241;Name=N481_E484delinsKGK;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=728;ao=45;dp=1854;sample_size=1924;Reference_seq=TGGTGTTG;Variant_seq=AGGTGTTG;nt_name=g.TGGTGTTG1443_1450AGGTA;aa_name=p.N481_E484delinsKGK;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Asn481_Glu484delinsLysGlyLys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024271844660194174;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	"ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=nan;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_218;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=K417N;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_218;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=K417N;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_218;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=K417N;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_218;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=outcome hazard ratio;source=https://doi.org/10.1101/2021.12.24.21268382v1.full;citation=Ulloa et al. (2021);comb_mutation=K417N;function_description=In Ontario, using a retrospective matched case (age, gender and onset date) study of 6,312 Omicron cases vs 8,875 Delta,  the adjusted risk of hospitalization or death was 54% lower (HR;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_212;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=transmissibility;source=https://doi.org/10.47326/ocsat.dashboard.2021.1.0;citation=nan et al. (2021);comb_mutation=S373P;function_description=On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_212;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=transmissibility;source=https://doi.org/10.47326/ocsat.dashboard.2021.1.0;citation=nan et al. (2021);comb_mutation=S373P;function_description=On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_212;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=transmissibility;source=https://doi.org/10.47326/ocsat.dashboard.2021.1.0;citation=nan et al. (2021);comb_mutation=S373P;function_description=On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_212;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=transmissibility;source=https://doi.org/10.47326/ocsat.dashboard.2021.1.0;citation=nan et al. (2021);comb_mutation=S373P;function_description=On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],  compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=N501Y;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=N501Y;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=N501Y;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=N501Y;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_216;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,N501Y;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_216;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,N501Y;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_216;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,N501Y;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_216;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,N501Y;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=N501Y;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=N501Y;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=N501Y;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=N501Y;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=N501Y;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_243;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=N501Y;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in all 4 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in all 4 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in all 4 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in all 4 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=reinfection;source=https://doi.org/10.1101/2021.11.11.21266068;citation=Pulliam et al. (2021);comb_mutation=nan;function_description=Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade  immunity from prior infection, evidenced by a reinfection hazard ratio of 2.39 (CI95: 1.88-3.11) relative to primary infection in the initial part of South Africa's 4th covid-19 wave (November 2021).  In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. [minimal variant signature for Omicron (B.1.1.529) used based on H69del PCR dropout observed in November 2021 coincident with the rise of Omicron];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=reinfection;source=https://doi.org/10.1101/2021.11.11.21266068;citation=Pulliam et al. (2021);comb_mutation=nan;function_description=Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade  immunity from prior infection, evidenced by a reinfection hazard ratio of 2.39 (CI95: 1.88-3.11) relative to primary infection in the initial part of South Africa's 4th covid-19 wave (November 2021).  In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. [minimal variant signature for Omicron (B.1.1.529) used based on H69del PCR dropout observed in November 2021 coincident with the rise of Omicron];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=reinfection;source=https://doi.org/10.1101/2021.11.11.21266068;citation=Pulliam et al. (2021);comb_mutation=nan;function_description=Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade  immunity from prior infection, evidenced by a reinfection hazard ratio of 2.39 (CI95: 1.88-3.11) relative to primary infection in the initial part of South Africa's 4th covid-19 wave (November 2021).  In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. [minimal variant signature for Omicron (B.1.1.529) used based on H69del PCR dropout observed in November 2021 coincident with the rise of Omicron];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23013	23013	.	+	.	ID=ID_242;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1075;ao=781;dp=1856;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4207974137931034;function_category=reinfection;source=https://doi.org/10.1101/2021.11.11.21266068;citation=Pulliam et al. (2021);comb_mutation=nan;function_description=Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade  immunity from prior infection, evidenced by a reinfection hazard ratio of 2.39 (CI95: 1.88-3.11) relative to primary infection in the initial part of South Africa's 4th covid-19 wave (November 2021).  In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. [minimal variant signature for Omicron (B.1.1.529) used based on H69del PCR dropout observed in November 2021 coincident with the rise of Omicron];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23018	23018	.	+	.	ID=ID_244;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1849;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9962284482758621;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23018	23018	.	+	.	ID=ID_244;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1849;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9962284482758621;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23018	23018	.	+	.	ID=ID_244;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1849;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9962284482758621;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23018	23018	.	+	.	ID=ID_244;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1849;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9962284482758621;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.22 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.17.504313;citation=Witte et al. (2022);comb_mutation=nan;function_description=Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1126/science.abf4830;citation=Rappazzo et al. (2021);comb_mutation=nan;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2020);comb_mutation=nan;function_description=Highly resistant to mAb SARS2-32 of 10 antibodies tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.06.10.447999;citation=Haslwanter et al. (2021);comb_mutation=nan;function_description=For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.01.014;citation=Liu et al. (2021);comb_mutation=nan;function_description=No effective neutralization in 3 out of the 4 sera tested.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.03.22.436481;citation=Sun et al. (2021);comb_mutation=nan;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2021);comb_mutation=nan;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_245;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=45;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=CC;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.024245689655172414;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.11.06.372037;citation=Liu et al. (2020);comb_mutation=nan;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_246;Name=F490P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=728;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=TC;nt_name=g.TT1468_1469CC;aa_name=p.F490P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe490Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3922413793103448;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_246;Name=F490P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=728;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=TC;nt_name=g.TT1468_1469CC;aa_name=p.F490P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe490Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3922413793103448;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=nan;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23030	23030	.	+	.	ID=ID_246;Name=F490P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1083;ao=728;dp=1856;sample_size=1924;Reference_seq=TT;Variant_seq=TC;nt_name=g.TT1468_1469CC;aa_name=p.F490P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe490Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3922413793103448;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.02.17.431683;citation=Starr et al. (2021);comb_mutation=nan;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23055	23055	.	+	.	ID=ID_247;Name=Q498R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1493G;aa_name=p.Q498R;hgvs_nt=NC_045512.2:g.1493A>G;hgvs_aa=YP_009724390.1:p.Gln498Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=N501Y;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23055	23055	.	+	.	ID=ID_247;Name=Q498R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1493G;aa_name=p.Q498R;hgvs_nt=NC_045512.2:g.1493A>G;hgvs_aa=YP_009724390.1:p.Gln498Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=N501Y;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23055	23055	.	+	.	ID=ID_247;Name=Q498R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1493G;aa_name=p.Q498R;hgvs_nt=NC_045512.2:g.1493A>G;hgvs_aa=YP_009724390.1:p.Gln498Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=N501Y;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23055	23055	.	+	.	ID=ID_247;Name=Q498R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1493G;aa_name=p.Q498R;hgvs_nt=NC_045512.2:g.1493A>G;hgvs_aa=YP_009724390.1:p.Gln498Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=N501Y;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23055	23055	.	+	.	ID=ID_247;Name=Q498R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1493G;aa_name=p.Q498R;hgvs_nt=NC_045512.2:g.1493A>G;hgvs_aa=YP_009724390.1:p.Gln498Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=N501Y;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23055	23055	.	+	.	ID=ID_247;Name=Q498R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1493G;aa_name=p.Q498R;hgvs_nt=NC_045512.2:g.1493A>G;hgvs_aa=YP_009724390.1:p.Gln498Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=N501Y;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.3390/pathogens10020184;citation=Flores-Alanis et al. (2021);comb_mutation=nan;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.3390/pathogens10020184;citation=Flores-Alanis et al. (2021);comb_mutation=nan;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.3390/pathogens10020184;citation=Flores-Alanis et al. (2021);comb_mutation=nan;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.3390/pathogens10020184;citation=Flores-Alanis et al. (2021);comb_mutation=nan;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.3390/pathogens10020184;citation=Flores-Alanis et al. (2021);comb_mutation=nan;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=nan;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=nan;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=nan;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=nan;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://doi.org/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=nan;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_250;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=H655Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_250;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=H655Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_250;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=H655Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_250;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=H655Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_250;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=H655Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=E484A;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=E484A;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=E484A;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=E484A;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2022.08.11.503601;citation=Wang et al. (2022);comb_mutation=E484A;function_description=3rd exposure to antigen by Delta (B.1.617.2) (n;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=nan;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_219;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_219;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_219;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_219;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_219;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.04.27.440939;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1002/smtd.202200387;citation=Feng et al. (2022);comb_mutation=nan;function_description=Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1002/smtd.202200387;citation=Feng et al. (2022);comb_mutation=nan;function_description=Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1002/smtd.202200387;citation=Feng et al. (2022);comb_mutation=nan;function_description=Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1002/smtd.202200387;citation=Feng et al. (2022);comb_mutation=nan;function_description=Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1002/smtd.202200387;citation=Feng et al. (2022);comb_mutation=nan;function_description=Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of β-strand, which inhibits binding with 20G6. 20G6 binds to a hidden  epitope on RBD which is highly conserved in sarbecoviruses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_216;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_216;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_216;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_216;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_216;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.491254;citation=Zhou et al. (2022);comb_mutation=R408S,E484A;function_description=In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has  the highest infection rate at 49.2%.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.11.491588;citation=Yuan et al. (2022);comb_mutation=E484A;function_description=Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa  (B.1.617.1) and VOCs including Delta (B.1.617.2).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2022.05.09.22274623;citation=Braeye et al. (2022);comb_mutation=E484A;function_description=In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection  against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=E484A;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=E484A;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=E484A;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=E484A;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_243;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view;citation=Sheward et al. (2021);comb_mutation=E484A;function_description=In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health  care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus  was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction was ~6x for the blood donors, and ~4.5x for the health care workers.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1136/bmj.n1943;citation=Chung et al. (2021);comb_mutation=nan;function_description=In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1136/bmj.n1943;citation=Chung et al. (2021);comb_mutation=nan;function_description=In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1136/bmj.n1943;citation=Chung et al. (2021);comb_mutation=nan;function_description=In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1136/bmj.n1943;citation=Chung et al. (2021);comb_mutation=nan;function_description=In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1136/bmj.n1943;citation=Chung et al. (2021);comb_mutation=nan;function_description=In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))  was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.05.18.444646;citation=Barton et al. (2021);comb_mutation=nan;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2020.12.29.424708;citation=nan et al. (2021);comb_mutation=nan;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2020.12.29.424708;citation=nan et al. (2021);comb_mutation=nan;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2020.12.29.424708;citation=nan et al. (2021);comb_mutation=nan;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2020.12.29.424708;citation=nan et al. (2021);comb_mutation=nan;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2020.12.29.424708;citation=nan et al. (2021);comb_mutation=nan;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=nan;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.02.428884;citation=Liu et al. (2021);comb_mutation=nan;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.14.431117;citation=Tian et al. (2021);comb_mutation=nan;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.11.426269;citation=Zhu et al. (2021);comb_mutation=nan;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.02.22.432359;citation=Ramanathan et al. (2021);comb_mutation=nan;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.09.439154;citation=Gamez et al. (2021);comb_mutation=nan;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.09.439154;citation=Gamez et al. (2021);comb_mutation=nan;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.09.439154;citation=Gamez et al. (2021);comb_mutation=nan;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.09.439154;citation=Gamez et al. (2021);comb_mutation=nan;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.04.09.439154;citation=Gamez et al. (2021);comb_mutation=nan;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_247;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=Q498R;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_247;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=Q498R;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_247;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=Q498R;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_247;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=Q498R;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_247;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=Q498R;function_description=Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,  forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears  to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative  to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with  this duo during in vitro evolution.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.04.02.438288;citation=Motozono et al. (2021);comb_mutation=nan;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.03.19.436183;citation=Tang et al. (2021);comb_mutation=nan;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.03.19.436183;citation=Tang et al. (2021);comb_mutation=nan;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.03.19.436183;citation=Tang et al. (2021);comb_mutation=nan;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.03.19.436183;citation=Tang et al. (2021);comb_mutation=nan;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.03.19.436183;citation=Tang et al. (2021);comb_mutation=nan;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=P681H;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_251;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=P681H;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=nan;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=nan;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=nan;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=nan;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=nan;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=nan;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=nan;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=nan;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=nan;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=nan;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1126/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=nan;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1126/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=nan;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1126/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=nan;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1126/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=nan;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1126/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=nan;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay. Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay. Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay. Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay. Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.15.426849;citation=Rees-Spear et al. (2021);comb_mutation=nan;function_description=Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay. Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.27.428516;citation=Shen et al. (2021);comb_mutation=nan;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.02.02.21250799;citation=Edara et al. (2021);comb_mutation=nan;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.02.02.21250799;citation=Edara et al. (2021);comb_mutation=nan;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.02.02.21250799;citation=Edara et al. (2021);comb_mutation=nan;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.02.02.21250799;citation=Edara et al. (2021);comb_mutation=nan;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.02.02.21250799;citation=Edara et al. (2021);comb_mutation=nan;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_248;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_221;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.04.21254881;citation=Bates et al. (2021);comb_mutation=nan;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=nan;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_231;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=L452R;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_231;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=L452R;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_231;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=L452R;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_231;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=L452R;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_231;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=L452R;function_description=The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.04.14.21255431;citation=Jacobson et al. (2021);comb_mutation=nan;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.01.15.426911;citation=Wang et al. (2021);comb_mutation=nan;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	"ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.04.15.21255389;citation=van Loon et al. (2021);comb_mutation=nan;function_description=In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.03.16.21253377;citation=Snell et al. (2021);comb_mutation=nan;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.03.16.21253377;citation=Snell et al. (2021);comb_mutation=nan;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.03.16.21253377;citation=Snell et al. (2021);comb_mutation=nan;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.03.16.21253377;citation=Snell et al. (2021);comb_mutation=nan;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23063	23063	.	+	.	ID=ID_249;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1854;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1101/2021.03.16.21253377;citation=Snell et al. (2021);comb_mutation=nan;function_description=A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=anthropozoonotic events;source=https://doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=nan;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=anthropozoonotic events;source=https://doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=nan;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=anthropozoonotic events;source=https://doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=nan;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=anthropozoonotic events;source=https://doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=nan;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=anthropozoonotic events;source=https://doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=nan;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=anthropozoonotic events;source=https://doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=nan;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23075	23075	.	+	.	ID=ID_252;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1852;dp=1853;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994603345925526;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=nan;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23198	23198	.	+	.	ID=ID_253;Name=L546L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1859;ao=10;dp=1869;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1636C;aa_name=p.L546L;hgvs_nt=NC_045512.2:g.1636T>C;hgvs_aa=YP_009724390.1:p.Leu546Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005350454788657036;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23222	23222	.	+	.	ID=ID_254;Name=E554K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=771;ao=1096;dp=1869;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G1660A;aa_name=p.E554K;hgvs_nt=NC_045512.2:g.1660G>A;hgvs_aa=YP_009724390.1:p.Glu554Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5864098448368111;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23245	23245	.	+	.	ID=ID_255;Name=P561P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1824;ao=44;dp=1868;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T1683C;aa_name=p.P561P;hgvs_nt=NC_045512.2:g.1683T>C;hgvs_aa=YP_009724390.1:p.Pro561Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.023554603854389723;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23271	23271	.	+	.	ID=ID_256;Name=A570V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=782;ao=1088;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1709T;aa_name=p.A570V;hgvs_nt=NC_045512.2:g.1709C>T;hgvs_aa=YP_009724390.1:p.Ala570Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5818181818181818;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23277	23277	.	+	.	ID=ID_257;Name=T572I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1841;ao=28;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1715T;aa_name=p.T572I;hgvs_nt=NC_045512.2:g.1715C>T;hgvs_aa=YP_009724390.1:p.Thr572Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014973262032085561;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in D614G variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in D614G variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in D614G variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in D614G variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in D614G variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in D614G variant from 391 RNA specimens.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation (a.k.a. ""Doug"") outside the receptor binding domain, while highly favorable to improved human-human transmission,  decreases transduction in naked mole-rat (Heterocephalus glaber)  fibroblast and Japanese pipistrelle bat (Pipistrellus abramus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1038/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=nan;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1016/j.cell.2020.09.032;citation=Yurkovetskiy et al. (2020);comb_mutation=nan;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2020.07.22.20159905;citation=Weissman et al. (2020);comb_mutation=nan;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=L452R;function_description=Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a somewhat less 3-fold increase];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=The L452R mutation increased the infectivity more than two-fold in these conditions.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=nan;function_description=Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=nan;function_description=Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=nan;function_description=Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=nan;function_description=Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=nan;function_description=Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=nan;function_description=Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 1.0x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=L452R;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=L452R;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=L452R;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=L452R;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=L452R;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine efficacy;source=https://doi.org/10.1101/2021.09.29.21264199;citation=Bruxvoort et al. (2021);comb_mutation=L452R;function_description=In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon. Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://doi.org/10.1038/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=nan;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://doi.org/10.1038/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=nan;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://doi.org/10.1038/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=nan;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://doi.org/10.1038/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=nan;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://doi.org/10.1038/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=nan;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://doi.org/10.1038/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=nan;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	"ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;"
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=nan;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=nan;function_description=1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_260;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_261;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_178;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=L452R;function_description=1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_262;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_262;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_262;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_262;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_262;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_262;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=P681R;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y,K417N;function_description=~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1101/2021.01.24.428007;citation=Barrett et al. (2021);comb_mutation=nan;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-020-19808-4;citation=nan et al. (2020);comb_mutation=nan;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.1038/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=nan;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/eLife.65365;citation=Daniloski et al. (2021);comb_mutation=nan;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/eLife.65365;citation=Daniloski et al. (2021);comb_mutation=nan;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/eLife.65365;citation=Daniloski et al. (2021);comb_mutation=nan;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/eLife.65365;citation=Daniloski et al. (2021);comb_mutation=nan;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/eLife.65365;citation=Daniloski et al. (2021);comb_mutation=nan;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/eLife.65365;citation=Daniloski et al. (2021);comb_mutation=nan;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_223;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_223;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_223;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_223;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_223;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_223;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.10.04.463028;citation=Mishra et al. (2021);comb_mutation=L452R;function_description=Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_230;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.08.09.21261704;citation=Wilhelm et al. (2021);comb_mutation=L452R;function_description=Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_248;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_220;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_221;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,K417N;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=nan;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_259;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=nan;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=nan;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=nan;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=nan;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=nan;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=nan;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://doi.org/10.3390/v13040633;citation=Kim et al. (2021);comb_mutation=nan;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://doi.org/10.1038/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=nan;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://doi.org/10.1038/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=nan;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://doi.org/10.1038/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=nan;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://doi.org/10.1038/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=nan;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://doi.org/10.1038/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=nan;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23403	23403	.	+	.	ID=ID_258;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://doi.org/10.1038/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=nan;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23423	23423	.	+	.	ID=ID_263;Name=P621S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=779;ao=1091;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1861T;aa_name=p.P621S;hgvs_nt=NC_045512.2:g.1861C>T;hgvs_aa=YP_009724390.1:p.Pro621Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5834224598930481;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.08.05.455290;citation=Esclera et al. (2021);comb_mutation=nan;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.08.05.455290;citation=Esclera et al. (2021);comb_mutation=nan;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.08.05.455290;citation=Esclera et al. (2021);comb_mutation=nan;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.08.05.455290;citation=Esclera et al. (2021);comb_mutation=nan;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.08.05.455290;citation=Esclera et al. (2021);comb_mutation=nan;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.08.05.455290;citation=Esclera et al. (2021);comb_mutation=nan;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_250;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=N501Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_250;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=N501Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_250;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=N501Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_250;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=N501Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_250;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=N501Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_250;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1101/2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=N501Y;function_description=Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain increases the virus transduction rate in tree shrew (Tupaia belangeri),  (as it does in humans) according to pseudotyped VSV experiments.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_264;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23525	23525	.	+	.	ID=ID_261;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.9x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=pharmaceutical effectiveness;source=https://doi.org/10.1101/2021.03.09.434607v9;citation=Cathcart et al. (2021);comb_mutation=nan;function_description=This individual mutation found in the epitope from Sotrovimab causes a 0.9x reduction in neutralization efficacy using a VSV model on Vero E6 cells.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=environmental condition stability;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=In the absence of N501Y, this Alpha lineage change in the furin clevage site did NOT show significant increase in infectivity relative to wild type,  as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.03.08.434499;citation=Liu et al. (2021);comb_mutation=nan;function_description=In the absence of N501Y, this Alpha lineage change in the furin clevage site did NOT show significant increase in infectivity relative to wild type,  as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=nan et al. (2021);comb_mutation=nan;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=nan et al. (2021);comb_mutation=nan;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=nan et al. (2021);comb_mutation=nan;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=nan et al. (2021);comb_mutation=nan;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.04.06.438731;citation=Lubinski et al. (2021);comb_mutation=nan;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=trafficking;source=https://doi.org/10.1101/2021.04.06.438731;citation=Lubinski et al. (2021);comb_mutation=nan;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=N501Y;function_description=These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=N501Y;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=N501Y;function_description=Slight neutralization improvement on average in 16 health workers' convalescent sera.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=N501Y;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_251;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=N501Y;function_description=One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.08.26.268854;citation=Johnson et al. (2020);comb_mutation=nan;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.08.26.268854;citation=Johnson et al. (2020);comb_mutation=nan;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.06.20248960;citation=Haynes et al. (2021);comb_mutation=nan;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.08.26.268854;citation=Johnson et al. (2020);comb_mutation=nan;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2020.08.26.268854;citation=Johnson et al. (2020);comb_mutation=nan;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_265;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=antibody epitope effects;source=https://doi.org/10.1038/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=nan;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=D614G;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_259;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=733;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.39197860962566844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.03.25.21253908;citation=Zuckerman et al. (2021);comb_mutation=D614G;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_266;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1137;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6080213903743316;function_category=virion structure;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_266;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1137;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6080213903743316;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_266;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1137;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6080213903743316;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_262;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1137;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6080213903743316;function_category=trafficking;source=https://doi.org/10.1101/2021.05.14.444076;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,  caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_266;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1137;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6080213903743316;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=nan et al. (2021);comb_mutation=nan;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work];heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23604	23604	.	+	.	ID=ID_190;Name=P681R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1137;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C2042G;aa_name=p.P681R;hgvs_nt=NC_045512.2:g.2042C>G;hgvs_aa=YP_009724390.1:p.Pro681Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.6080213903743316;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1101/2021.06.28.449914;citation=Choi et al. (2021);comb_mutation=F157L;function_description=Neutralization efficiency (ID50) against A.23.1-v1 reduced 1.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_267;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_267;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_267;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=virion structure;source=https://doi.org/10.1101/2021.03.24.436850;citation=Spratt et al. (2021);comb_mutation=nan;function_description=Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_267;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=antibody epitope effects;source=https://doi.org/10.1101/2022.05.28.22275691;citation=Hernandez et al. (2022);comb_mutation=nan;function_description=Using the Agena MassARRAY® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_260;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=convalescent plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_260;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_260;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=vaccinee plasma binding;source=https://doi.org/10.1101/2021.08.04.455140;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23664	23664	.	+	.	ID=ID_267;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1799;ao=50;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02704164413196322;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	23986	23986	.	+	.	ID=ID_268;Name=D808D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1831;ao=14;dp=1845;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T2424C;aa_name=p.D808D;hgvs_nt=NC_045512.2:g.2424T>C;hgvs_aa=YP_009724390.1:p.Asp808Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007588075880758808;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24130	24130	.	+	.	ID=ID_269;Name=N856N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1836;ao=11;dp=1847;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2568T;aa_name=p.N856N;hgvs_nt=NC_045512.2:g.2568C>T;hgvs_aa=YP_009724390.1:p.Asn856Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005955603681645912;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24337	24337	.	+	.	ID=ID_270;Name=N925N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1837;ao=13;dp=1850;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2775T;aa_name=p.N925N;hgvs_nt=NC_045512.2:g.2775C>T;hgvs_aa=YP_009724390.1:p.Asn925Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007027027027027027;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24346	24346	.	+	.	ID=ID_271;Name=N928N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1835;ao=16;dp=1851;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T2784C;aa_name=p.N928N;hgvs_nt=NC_045512.2:g.2784T>C;hgvs_aa=YP_009724390.1:p.Asn928Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00864397622906537;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24378	24378	.	+	.	ID=ID_272;Name=S939F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=774;ao=1075;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2816T;aa_name=p.S939F;hgvs_nt=NC_045512.2:g.2816C>T;hgvs_aa=YP_009724390.1:p.Ser939Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5813953488372093;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain significantly reduced the tropism of SARS-CoV-2 to MfuKi (eastern bent-wing bat kidney cell, Miniopterus fuliginosus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24378	24378	.	+	.	ID=ID_272;Name=S939F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=774;ao=1075;dp=1849;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C2816T;aa_name=p.S939F;hgvs_nt=NC_045512.2:g.2816C>T;hgvs_aa=YP_009724390.1:p.Ser939Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5813953488372093;function_category=anthropozoonotic events;source=https://doi.org/10.1038/s41396-023-01368-2;citation=Li et al. (2023);comb_mutation=nan;function_description=This mutation outside the receptor binding domain significantly reduced the tropism of SARS-CoV-2 to MfuKi (eastern bent-wing bat kidney cell, Miniopterus fuliginosus) cell cultures using a pseudotyped VSV assay.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24863	24863	.	+	.	ID=ID_273;Name=H1101Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1860;ao=10;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3301T;aa_name=p.H1101Y;hgvs_nt=NC_045512.2:g.3301C>T;hgvs_aa=YP_009724390.1:p.His1101Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	24990	24990	.	+	.	ID=ID_274;Name=P1143L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=779;ao=1088;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3428T;aa_name=p.P1143L;hgvs_nt=NC_045512.2:g.3428C>T;hgvs_aa=YP_009724390.1:p.Pro1143Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.582441113490364;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25000	25000	.	+	.	ID=ID_275;Name=D1146D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1869;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3438T;aa_name=p.D1146D;hgvs_nt=NC_045512.2:g.3438C>T;hgvs_aa=YP_009724390.1:p.Asp1146Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25083	25083	.	+	.	ID=ID_276;Name=A1174V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3521T;aa_name=p.A1174V;hgvs_nt=NC_045512.2:g.3521C>T;hgvs_aa=YP_009724390.1:p.Ala1174Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25207	25207	.	+	.	ID=ID_277;Name=Y1215Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=779;ao=1087;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3645T;aa_name=p.Y1215Y;hgvs_nt=NC_045512.2:g.3645C>T;hgvs_aa=YP_009724390.1:p.Tyr1215Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.582529474812433;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25249	25249	.	+	.	ID=ID_278;Name=M1229I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1754;ao=109;dp=1864;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G3687T;aa_name=p.M1229I;hgvs_nt=NC_045512.2:g.3687G>T;hgvs_aa=YP_009724390.1:p.Met1229Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05847639484978541;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25249	25249	.	+	.	ID=ID_278;Name=M1229I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1754;ao=109;dp=1864;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G3687T;aa_name=p.M1229I;hgvs_nt=NC_045512.2:g.3687G>T;hgvs_aa=YP_009724390.1:p.Met1229Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05847639484978541;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25249	25249	.	+	.	ID=ID_278;Name=M1229I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1754;ao=109;dp=1864;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G3687T;aa_name=p.M1229I;hgvs_nt=NC_045512.2:g.3687G>T;hgvs_aa=YP_009724390.1:p.Met1229Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05847639484978541;function_category=trafficking;source=https://doi.org/10.1101/2021.02.05.430003;citation=Tada et al. (2021);comb_mutation=nan;function_description=Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness.;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25290	25290	.	+	.	ID=ID_279;Name=C1243S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1849;ao=16;dp=1865;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G3728C;aa_name=p.C1243S;hgvs_nt=NC_045512.2:g.3728G>C;hgvs_aa=YP_009724390.1:p.Cys1243Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008579088471849867;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25327	25327	.	+	.	ID=ID_280;Name=K1255K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1849;ao=14;dp=1863;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A3765G;aa_name=p.K1255K;hgvs_nt=NC_045512.2:g.3765A>G;hgvs_aa=YP_009724390.1:p.Lys1255Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007514761137949544;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25355	25355	.	+	.	ID=ID_281;Name=L1265F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1851;ao=11;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C3793T;aa_name=p.L1265F;hgvs_nt=NC_045512.2:g.3793C>T;hgvs_aa=YP_009724390.1:p.Leu1265Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005907626208378088;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25416	25416	.	+	.	ID=ID_282;Name=F8F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1089;ao=780;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C24T;aa_name=p.F8F;hgvs_nt=NC_045512.2:g.24C>T;hgvs_aa=YP_009724391.1:p.Phe8Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4173354735152488;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25429	25429	.	+	.	ID=ID_283;Name=V13L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1821;ao=48;dp=1869;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G37T;aa_name=p.V13L;hgvs_nt=NC_045512.2:g.37G>T;hgvs_aa=YP_009724391.1:p.Val13Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025682182985553772;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25572	25572	.	+	.	ID=ID_284;Name=S60S;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1741;ao=128;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C180T;aa_name=p.S60S;hgvs_nt=NC_045512.2:g.180C>T;hgvs_aa=YP_009724391.1:p.Ser60Ser;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06848582129481005;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25584	25584	.	+	.	ID=ID_285;Name=T64T;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C192T;aa_name=p.T64T;hgvs_nt=NC_045512.2:g.192C>T;hgvs_aa=YP_009724391.1:p.Thr64Thr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25650	25650	.	+	.	ID=ID_286;Name=L86F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1860;ao=10;dp=1870;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G258T;aa_name=p.L86F;hgvs_nt=NC_045512.2:g.258G>T;hgvs_aa=YP_009724391.1:p.Leu86Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25797	25797	.	+	.	ID=ID_287;Name=K136L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1848;ao=18;dp=1867;sample_size=1924;Reference_seq=CAA;Variant_seq=TCT;nt_name=g.CAA405_407TCT;aa_name=p.K136L;hgvs_nt=n/a;hgvs_aa=YP_009724391.1:p.Lys136Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0096411355115158;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25810	25810	.	+	.	ID=ID_288;Name=L140F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1852;ao=14;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C418T;aa_name=p.L140F;hgvs_nt=NC_045512.2:g.418C>T;hgvs_aa=YP_009724391.1:p.Leu140Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007502679528403001;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	25916	25916	.	+	.	ID=ID_289;Name=T175I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1851;ao=11;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C524T;aa_name=p.T175I;hgvs_nt=NC_045512.2:g.524C>T;hgvs_aa=YP_009724391.1:p.Thr175Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005894962486602358;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26060	26060	.	+	.	ID=ID_290;Name=T223I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C668T;aa_name=p.T223I;hgvs_nt=NC_045512.2:g.668C>T;hgvs_aa=YP_009724391.1:p.Thr223Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26111	26111	.	+	.	ID=ID_291;Name=P240L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1854;ao=12;dp=1866;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C719T;aa_name=p.P240L;hgvs_nt=NC_045512.2:g.719C>T;hgvs_aa=YP_009724391.1:p.Pro240Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006430868167202572;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26184	26184	.	+	.	ID=ID_292;Name=Y264Y;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1854;ao=12;dp=1866;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T792C;aa_name=p.Y264Y;hgvs_nt=NC_045512.2:g.792T>C;hgvs_aa=YP_009724391.1:p.Tyr264Tyr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006430868167202572;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (11x overrepresentation vs expected count of ~300 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (11x overrepresentation vs expected count of ~300 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (11x overrepresentation vs expected count of ~300 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (11x overrepresentation vs expected count of ~300 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26270	26270	.	+	.	ID=ID_293;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=6;ao=1861;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9967862881628281;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26275	26275	.	+	.	ID=ID_294;Name=T11A;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1087;ao=780;dp=1867;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A31G;aa_name=p.T11A;hgvs_nt=NC_045512.2:g.31A>G;hgvs_aa=YP_009724392.1:p.Thr11Ala;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4177825388323514;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26484	26484	.	+	.	ID=ID_295;Name=g.-38_-37delTT;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1817;ao=48;dp=1865;sample_size=1924;Reference_seq=ATT;Variant_seq=A;nt_name=g.-38_-37delTT;aa_name=;hgvs_nt=NC_045512.2:g.-38_-37del;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=M;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025737265415549597;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26529	26529	.	+	.	ID=ID_296;Name=D3H;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=781;ao=1087;dp=1868;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G7C;aa_name=p.D3H;hgvs_nt=NC_045512.2:g.7G>C;hgvs_aa=YP_009724393.1:p.Asp3His;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5819057815845824;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (227x overrepresentation vs expected count of ~14 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26529	26529	.	+	.	ID=ID_296;Name=D3H;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=781;ao=1087;dp=1868;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G7C;aa_name=p.D3H;hgvs_nt=NC_045512.2:g.7G>C;hgvs_aa=YP_009724393.1:p.Asp3His;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5819057815845824;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (227x overrepresentation vs expected count of ~14 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26529	26529	.	+	.	ID=ID_296;Name=D3H;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=781;ao=1087;dp=1868;sample_size=1924;Reference_seq=G;Variant_seq=C;nt_name=g.G7C;aa_name=p.D3H;hgvs_nt=NC_045512.2:g.7G>C;hgvs_aa=YP_009724393.1:p.Asp3His;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5819057815845824;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (227x overrepresentation vs expected count of ~14 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26577	26577	.	+	.	ID=ID_297;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26577	26577	.	+	.	ID=ID_297;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26577	26577	.	+	.	ID=ID_297;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26577	26577	.	+	.	ID=ID_297;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26577	26577	.	+	.	ID=ID_297;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26577	26577	.	+	.	ID=ID_297;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (16x overrepresentation vs expected count of ~8 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26586	26586	.	+	.	ID=ID_298;Name=L22L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1824;ao=44;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C64T;aa_name=p.L22L;hgvs_nt=NC_045512.2:g.64C>T;hgvs_aa=YP_009724393.1:p.Leu22Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.023554603854389723;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26609	26609	.	+	.	ID=ID_299;Name=L29L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1858;ao=10;dp=1868;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T87C;aa_name=p.L29L;hgvs_nt=NC_045512.2:g.87T>C;hgvs_aa=YP_009724393.1:p.Leu29Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053533190578158455;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26610	26610	.	+	.	ID=ID_300;Name=T30A;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=781;ao=1060;dp=1841;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A88G;aa_name=p.T30A;hgvs_nt=NC_045512.2:g.88A>G;hgvs_aa=YP_009724393.1:p.Thr30Ala;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5757740358500815;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26645	26645	.	+	.	ID=ID_301;Name=N41N;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1844;ao=24;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C123T;aa_name=p.N41N;hgvs_nt=NC_045512.2:g.123C>T;hgvs_aa=YP_009724393.1:p.Asn41Asn;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01284796573875803;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (19x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26681	26681	.	+	.	ID=ID_302;Name=F53F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=775;ao=1093;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C159T;aa_name=p.F53F;hgvs_nt=NC_045512.2:g.159C>T;hgvs_aa=YP_009724393.1:p.Phe53Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5851177730192719;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (163x overrepresentation vs expected count of ~567 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26709	26709	.	+	.	ID=ID_303;Name=A63T;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1868;dp=1868;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G187A;aa_name=p.A63T;hgvs_nt=NC_045512.2:g.187G>A;hgvs_aa=YP_009724393.1:p.Ala63Thr;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26833	26833	.	+	.	ID=ID_304;Name=A104V;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=783;ao=1087;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C311T;aa_name=p.A104V;hgvs_nt=NC_045512.2:g.311C>T;hgvs_aa=YP_009724393.1:p.Ala104Val;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5812834224598931;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26837	26837	.	+	.	ID=ID_305;Name=R105R;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1856;ao=13;dp=1869;sample_size=1924;Reference_seq=T;Variant_seq=G;nt_name=g.T315G;aa_name=p.R105R;hgvs_nt=NC_045512.2:g.315T>G;hgvs_aa=YP_009724393.1:p.Arg105Arg;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006955591225254147;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26858	26858	.	+	.	ID=ID_306;Name=F112F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1869;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C336T;aa_name=p.F112F;hgvs_nt=NC_045512.2:g.336C>T;hgvs_aa=YP_009724393.1:p.Phe112Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994652406417113;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (11x overrepresentation vs expected count of ~463 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26858	26858	.	+	.	ID=ID_306;Name=F112F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1869;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C336T;aa_name=p.F112F;hgvs_nt=NC_045512.2:g.336C>T;hgvs_aa=YP_009724393.1:p.Phe112Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9994652406417113;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (11x overrepresentation vs expected count of ~463 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26873	26873	.	+	.	ID=ID_307;Name=N117N;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1860;ao=10;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C351T;aa_name=p.N117N;hgvs_nt=NC_045512.2:g.351C>T;hgvs_aa=YP_009724393.1:p.Asn117Asn;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0053475935828877;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (29x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26885	26885	.	+	.	ID=ID_308;Name=N121N;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1831;ao=39;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C363T;aa_name=p.N121N;hgvs_nt=NC_045512.2:g.363C>T;hgvs_aa=YP_009724393.1:p.Asn121Asn;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02085561497326203;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	26945	26945	.	+	.	ID=ID_309;Name=G141G;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1859;ao=11;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A423G;aa_name=p.G141G;hgvs_nt=NC_045512.2:g.423A>G;hgvs_aa=YP_009724393.1:p.Gly141Gly;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0058823529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27059	27059	.	+	.	ID=ID_310;Name=Y179Y;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1857;ao=11;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C537T;aa_name=p.Y179Y;hgvs_nt=NC_045512.2:g.537C>T;hgvs_aa=YP_009724393.1:p.Tyr179Tyr;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005888650963597431;function_category=frequency based fitness;source=https://doi.org/10.1101/2023.01.30.526314;citation=nan et al. (2023);comb_mutation=nan;function_description=Calculated to have an increased fitness (10x overrepresentation vs expected count of ~572 in public genome datasets), analysis as of 2023-05-11;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27259	27259	.	+	.	ID=ID_311;Name=R20R;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1869;dp=1869;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A58C;aa_name=p.R20R;hgvs_nt=NC_045512.2:g.58A>C;hgvs_aa=YP_009724394.1:p.Arg20Arg;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27313	27313	.	+	.	ID=ID_312;Name=K38E;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1856;ao=12;dp=1868;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A112G;aa_name=p.K38E;hgvs_nt=NC_045512.2:g.112A>G;hgvs_aa=YP_009724394.1:p.Lys38Glu;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006423982869379015;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27382	27382	.	+	.	ID=ID_313;Name=D61L;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1865;dp=1865;sample_size=1924;Reference_seq=GAT;Variant_seq=CTC;nt_name=g.GAT181_183CTC;aa_name=p.D61L;hgvs_nt=n/a;hgvs_aa=YP_009724394.1:p.Asp61Leu;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27476	27476	.	+	.	ID=ID_314;Name=T28I;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1839;ao=25;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C83T;aa_name=p.T28I;hgvs_nt=NC_045512.2:g.83C>T;hgvs_aa=YP_009724395.1:p.Thr28Ile;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.013412017167381975;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27507	27507	.	+	.	ID=ID_315;Name=G38G;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1254;ao=607;dp=1862;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A114C;aa_name=p.G38G;hgvs_nt=NC_045512.2:g.114A>C;hgvs_aa=YP_009724395.1:p.Gly38Gly;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3259935553168636;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27651	27651	.	+	.	ID=ID_316;Name=L86L;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1825;ao=40;dp=1865;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G258A;aa_name=p.L86L;hgvs_nt=NC_045512.2:g.258G>A;hgvs_aa=YP_009724395.1:p.Leu86Leu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.021447721179624665;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27684	27684	.	+	.	ID=ID_317;Name=Y97Y;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1852;ao=13;dp=1865;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C291T;aa_name=p.Y97Y;hgvs_nt=NC_045512.2:g.291C>T;hgvs_aa=YP_009724395.1:p.Tyr97Tyr;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006970509383378016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27807	27807	.	+	.	ID=ID_318;Name=F19L;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=973;dp=1866;sample_size=1924;Reference_seq=CTAT;Variant_seq=TTAC;nt_name=g.CTAT52_55TTAC;aa_name=p.F19L;hgvs_nt=n/a;hgvs_aa=YP_009725318.1:p.Phe19Leu;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5214362272240086;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27807	27807	.	+	.	ID=ID_319;Name=L18L;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=892;dp=1866;sample_size=1924;Reference_seq=CTAT;Variant_seq=TTAT;nt_name=g.C52T;aa_name=p.L18L;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009725318.1:p.Leu18Leu;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4780278670953912;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27883	27883	.	+	.	ID=ID_320;Name=A43V;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1852;ao=12;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C128T;aa_name=p.A43V;hgvs_nt=NC_045512.2:g.128C>T;hgvs_aa=YP_009725318.1:p.Ala43Val;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.006437768240343348;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27915	27915	.	+	.	ID=ID_321;Name=G8X;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1092;ao=770;dp=1862;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G22T;aa_name=p.G8X;hgvs_nt=NC_045512.2:g.22G>T;hgvs_aa=YP_009724396.1:p.Gly8Xaa;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.41353383458646614;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	27945	27945	.	+	.	ID=ID_322;Name=Q18X;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1851;ao=11;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.Q18X;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724396.1:p.Gln18Xaa;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005907626208378088;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28001	28001	.	+	.	ID=ID_323;Name=P36P;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1845;ao=14;dp=1859;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G108A;aa_name=p.P36P;hgvs_nt=NC_045512.2:g.108G>A;hgvs_aa=YP_009724396.1:p.Pro36Pro;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007530930607853685;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28077	28077	.	+	.	ID=ID_324;Name=V62L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1839;ao=13;dp=1854;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G184T;aa_name=p.V62L;hgvs_nt=NC_045512.2:g.184G>T;hgvs_aa=YP_009724396.1:p.Val62Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007011866235167206;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28079	28079	.	+	.	ID=ID_325;Name=V62V;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1829;ao=24;dp=1853;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G186T;aa_name=p.V62V;hgvs_nt=NC_045512.2:g.186G>T;hgvs_aa=YP_009724396.1:p.Val62Val;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.012951969778737183;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28087	28087	.	+	.	ID=ID_326;Name=A65V;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1778;ao=73;dp=1851;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C194T;aa_name=p.A65V;hgvs_nt=NC_045512.2:g.194C>T;hgvs_aa=YP_009724396.1:p.Ala65Val;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03943814154511075;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28104	28104	.	+	.	ID=ID_327;Name=I71V;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1831;ao=22;dp=1853;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A211G;aa_name=p.I71V;hgvs_nt=NC_045512.2:g.211A>G;hgvs_aa=YP_009724396.1:p.Ile71Val;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011872638963842417;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28201	28201	.	+	.	ID=ID_328;Name=S103L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1842;ao=20;dp=1862;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C308T;aa_name=p.S103L;hgvs_nt=NC_045512.2:g.308C>T;hgvs_aa=YP_009724396.1:p.Ser103Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010741138560687433;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28253	28253	.	+	.	ID=ID_329;Name=I121fs;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1832;ao=24;dp=1863;sample_size=1924;Reference_seq=CA;Variant_seq=C;nt_name=g.361delA;aa_name=p.I121fs;hgvs_nt=NC_045512.2:g.361del;hgvs_aa=YP_009724396.1:p.Ile121fs;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01288244766505636;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28271	28271	.	+	.	ID=ID_330;Name=g.A-3T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=A;Variant_seq=T;nt_name=g.A-3T;aa_name=;hgvs_nt=NC_045512.2:g.3A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28282	28282	.	+	.	ID=ID_331;Name=D3D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1795;ao=72;dp=1867;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T9C;aa_name=p.D3D;hgvs_nt=NC_045512.2:g.9T>C;hgvs_aa=YP_009724397.2:p.Asp3Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0385645420460632;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28297	28297	.	+	.	ID=ID_332;Name=N8N;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1169;ao=698;dp=1867;sample_size=1924;Reference_seq=T;Variant_seq=C;nt_name=g.T24C;aa_name=p.N8N;hgvs_nt=NC_045512.2:g.24T>C;hgvs_aa=YP_009724397.2:p.Asn8Asn;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3738618103910016;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://doi.org/10.1101/2021.05.19.444774;citation=Borges et al. (2021);comb_mutation=nan;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28311	28311	.	+	.	ID=ID_333;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1867;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://doi.org/10.1101/2021.04.08.438904;citation=de Silva et al. (2021);comb_mutation=nan;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28361	28361	.	+	.	ID=ID_334;Name=E31_S33del;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1854;dp=1856;sample_size=1924;Reference_seq=GGAGAACGCA;Variant_seq=G;nt_name=g.90_98delAGAACGCAG;aa_name=p.E31_S33del;hgvs_nt=NC_045512.2:g.90_98del;hgvs_aa=YP_009724397.2:p.Glu31_Ser33del;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9989224137931034;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28447	28447	.	+	.	ID=ID_335;Name=Q58Q;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1845;ao=19;dp=1864;sample_size=1924;Reference_seq=A;Variant_seq=G;nt_name=g.A174G;aa_name=p.Q58Q;hgvs_nt=NC_045512.2:g.174A>G;hgvs_aa=YP_009724397.2:p.Gln58Gln;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0101931330472103;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28603	28603	.	+	.	ID=ID_336;Name=F110F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1851;ao=16;dp=1867;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C330T;aa_name=p.F110F;hgvs_nt=NC_045512.2:g.330C>T;hgvs_aa=YP_009724397.2:p.Phe110Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00856989823245849;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28621	28621	.	+	.	ID=ID_337;Name=G116G;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1826;ao=39;dp=1866;sample_size=1924;Reference_seq=G;Variant_seq=A;nt_name=g.G348A;aa_name=p.G116G;hgvs_nt=NC_045512.2:g.348G>A;hgvs_aa=YP_009724397.2:p.Gly116Gly;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02090032154340836;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28657	28657	.	+	.	ID=ID_338;Name=D128D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1854;ao=14;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C384T;aa_name=p.D128D;hgvs_nt=NC_045512.2:g.384C>T;hgvs_aa=YP_009724397.2:p.Asp128Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007494646680942184;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28877	28877	.	+	.	ID=ID_339;Name=RG203KR;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=40;dp=1870;sample_size=1924;Reference_seq=AGTAGGG;Variant_seq=TCTAAAC;nt_name=g.AGTAGGG604_610TCTAAAC;aa_name=p.RG203KR;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.ArgGly203LysArg;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0213903743315508;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28877	28877	.	+	.	ID=ID_339;Name=RG203KR;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1828;dp=1870;sample_size=1924;Reference_seq=AGTAGGG;Variant_seq=AGTAAAC;nt_name=g.GGG608_610AAC;aa_name=p.RG203KR;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.ArgGly203LysArg;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9775401069518717;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	28958	28958	.	+	.	ID=ID_340;Name=Q229K;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=784;ao=1086;dp=1870;sample_size=1924;Reference_seq=C;Variant_seq=A;nt_name=g.C685A;aa_name=p.Q229K;hgvs_nt=NC_045512.2:g.685C>A;hgvs_aa=YP_009724397.2:p.Gln229Lys;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5807486631016042;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29140	29140	.	+	.	ID=ID_341;Name=Q289H;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1854;ao=15;dp=1869;sample_size=1924;Reference_seq=G;Variant_seq=T;nt_name=g.G867T;aa_name=p.Q289H;hgvs_nt=NC_045512.2:g.867G>T;hgvs_aa=YP_009724397.2:p.Gln289His;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.008025682182985553;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29218	29218	.	+	.	ID=ID_342;Name=F315F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1852;ao=17;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C945T;aa_name=p.F315F;hgvs_nt=NC_045512.2:g.945C>T;hgvs_aa=YP_009724397.2:p.Phe315Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.00909577314071696;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29353	29353	.	+	.	ID=ID_343;Name=Y360Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1858;ao=11;dp=1869;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1080T;aa_name=p.Y360Y;hgvs_nt=NC_045512.2:g.1080C>T;hgvs_aa=YP_009724397.2:p.Tyr360Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.005885500267522739;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29386	29386	.	+	.	ID=ID_344;Name=D371D;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1843;ao=21;dp=1864;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C1113T;aa_name=p.D371D;hgvs_nt=NC_045512.2:g.1113C>T;hgvs_aa=YP_009724397.2:p.Asp371Asp;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011266094420600859;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29510	29510	.	+	.	ID=ID_345;Name=S413R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=0;ao=1870;dp=1870;sample_size=1924;Reference_seq=A;Variant_seq=C;nt_name=g.A1237C;aa_name=p.S413R;hgvs_nt=NC_045512.2:g.1237A>C;hgvs_aa=YP_009724397.2:p.Ser413Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29625	29625	.	+	.	ID=ID_346;Name=S23F;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1265;ao=603;dp=1868;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C68T;aa_name=p.S23F;hgvs_nt=NC_045512.2:g.68C>T;hgvs_aa=YP_009725255.1:p.Ser23Phe;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3228051391862955;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29733	29733	.	+	.	ID=ID_347;Name=g.CGAGGCCACGCGGAGTACGATCGAGTG29733C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=1;ao=1114;dp=1115;sample_size=1924;Reference_seq=CGAGGCCACGCGGAGTACGATCGAGTG;Variant_seq=C;nt_name=g.CGAGGCCACGCGGAGTACGATCGAGTG29733C;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9991031390134529;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=True;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
NC_045512.2	.	.	29784	29784	.	+	.	ID=ID_348;Name=g.C29784T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=;ro=944;ao=177;dp=1121;sample_size=1924;Reference_seq=C;Variant_seq=T;nt_name=g.C29784T;aa_name=;hgvs_nt=NC_045512.2:g.29784C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=2023-12-25_2023-12-31;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.15789473684210525;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=;clade_defining=False;variant=n/a;variant_type=n/a;voi_designation_date=n/a;voc_designation_date=n/a;vum_designation_date=n/a;status=n/a;
